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Abstract 
The p90 ribosomal S6 kinases (RSKs) are a family of serine/threonine kinases consisting of 
four isoforms (RSK1-4), which regulate key cellular processes including cell cycle, 
proliferation, motility and survival. Among the several transcription factors targeted by RSKs, 
several studies have identified the Steroid Receptors (SRs) as substrates of the RSKs. SRs 
are a subfamily of the nuclear receptor superfamily consisting of five proteins (androgen, 
glucocorticoid, estrogen, progesterone and mineralocorticoid receptors). These proteins 
regulate gene expression thus are involved in crucial biological processes, including organ 
development and maintenance, the immune system, neuroprotection and metabolic 
homeostasis. Importantly, SRs are the main drivers of hormone driven cancers. Therefore, 
we hypothesised that the RSKs could play an important part in SR signalling within hormone 
driven cancer development and progression.  
This was investigated using recombinant DNA techniques to incorporate the RSKs genes 
into the mammalian expression vector PCDNA 3.1(+) and to produce phospho-mimetic 
mutants. Luciferase assays were used to determine optimal hormone and DNA 
concentrations, the role of RSKs on SR activity, the activity of the endogenous MAPK 
pathway and the significance of phosphorylation state. The PMA experiments indicated that 
in most cases PMA does not induce a significant change to RSK activity, thus the 
endogenous MAPK pathway is sufficiently active. The mutant experiments suggested that 
the phospho-mimetic mutation used does not cause constitutive activation of the RSKs. 
Together considering all experiments it was illustrated that the RSKs have differential effects 
on SR signalling. All the RSKs increased AR and GR activity despite some contradictions 
within the data. RSK4 significantly decreased ERα activity and RSK3 significantly increased 
PR activity. 
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Chapter 1 – Introduction 
 
1.1 - RSK Structure and Expression 
The 90 kDa ribosomal S6 kinases (RSKs) are a family of serine/threonine kinases composed 
of four isoforms (RSK 1-4). The isoforms range from 733-745 amino acids long and share 
between 73-80% total sequence identity (Figure 1.1.1). The general structure of the RSKs is 
characterised with two key kinase domains, the C-terminal kinase domain (CTKD) which is 
closely related to the calcium/calmodulin-dependent protein kinases (CAMK) and the N-
terminal kinase domain (NTKD) which is closely related to AGC kinases. This unique protein 
structure originates from a gene fusion event (Jones et al. 1988). The two kinase domains 
have high sequence identity among the 4 isoforms, while the N- and C-terminus are not 
conserved. The CTKD and NTKD are joined together by a linker region of approximately 100 
amino acids containing the turn motif (TM) and the hydrophobic motif (HM), which are key 
regulatory domains, with a reduced sequence identity (49-67%). The C-terminus contains 
the ERK D-domain (D-d) required for ERK1/2 docking which is indispensable for protein 
activation (Lara et al. 2013).   
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Figure 1.1.1 Schematic representation of RSK functional domains and homology 
between the kinases. Above schematic is a percentage of the amino acid sequence identity 
shared between the different RSK isoforms at different domains across the shared structure 
compared to RSK1. The N-terminal Kinase Domain (NTKD) is preceded by the variable N-
terminus. Following the NTKD in the hinger region which possesses the Turn Motif (TM) and 
the Hydrophobic Motif (HM). Following the hinger region is the C-terminal kinase domain 
CTKD which proceeds into the ERK docking domain (D-d) (adapted from Lara et al., 2013). 
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The RSKs are ubiquitously expressed across the adult human body but the levels of 
expression vary dependent on tissues type. RSK1 exhibits higher expression in the 
hematopoietic system, gastrointestinal tract and the female sex organs but also shows 
reduced expression in adipose and soft tissue. RSK2 has relatively high expression across 
most tissues but shows a reduction in expression in adipose and soft tissue. RSK3 has 
moderate expression across most tissues but shows enhanced expression in endocrine 
tissues and reduced expression in adipose and soft tissue. RSK4 has moderate expression 
across most tissues but displays reduced expression in muscle tissues (Uhlén et al. 2015).  
1.2 - Cellular Localisation 
In non-dividing cells RSK1-3 mostly reside in the cytoplasm awaiting activation. Once growth 
factor stimulation occurs the RSKs become activated by ERK the downstream activator of 
the MAPK pathway (Chen et al. 1992). Once activated the RSKs translocate to the nucleus 
via an unknown mechanism. RSK3 is the only isoform to possess a Nuclear Localisation 
Sequence (NLS), however its functionality has never been tested. Once in the nucleus the 
RSKs phosphorylate their corresponding substrate targets. RSK2 has also been shown to 
translocate to stress granules when under oxidative stress. Differently from the other RSKs, 
RSK4 is growth factor independent and is predominantly a cytoplasmic protein (Cargnello & 
Roux 2011).  
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1.3 - RSK Activation  
Recent evidences have shown that different RSK isoforms are activated in different ways, 
with RSK1-3 sharing a relatively similar mechanism and RSK4 deviating from this canonical 
mechanism. As such, RSK4 will be discussed separately. RSK 1-3 are primarily downstream 
effectors of the mitogen activated protein kinases (MAPK) signalling cascade. The 
extracellular signal can be produced by several growth factors or hormones, which bind to 
and activate Receptor Tyrosine Kinases (RTKs) present on the extracellular surface of the 
cell membrane (Hilger et al. 2002). The stimulated RTK dimerises leading to 
autophosphorylation of the receptors cytoplasmic domain and initiation of the intrinsic signal. 
Presentation of phosphorylated tyrosines on the RTK cytoplasmic domain are recognised by 
growth-factor-receptor-bound-protein 2 (Grb2) which in turn recruits Sons Of Sevenless 
(SOS). SOS is a guanine exchange factor which causes the GDP/GTP exchange in 
membrane bound Ras causing a structural change into its active conformation (Hilger et al. 
2002). Active Ras then binds to the kinase Raf (most commonly to the B-Raf isoform), 
causing its translocation to the intracellular surface of the cell membrane and activation. Raf 
then phosphorylates two serine residues on the kinase MEK1/2 activation loop. MEK1/2 then 
phosphorylates ERK (Kolch., 2000). Unusually inactive ERK is found in a pre-existing 
complex with inactive RSK1-4 in the cytoplasm, bound via the D-domain of the RSKs (Hsiao 
et al. 1994) although the function of this complex is unknown. The docking of ERK to the D-
domain of RSKs requires a minimal sequence LAQRR which is conserved across all 
isoforms (Smith et al. 1999). In a broader sense the docking of ERK requires a cluster of 
positive amino acid residues encompassed by hydrophobic residues (Tanoue & Nishida 
2003). When ERK is activated it phosphorylates the CTKD of RSK 1-3 at amino acids 
Thr573, Thr577 and Thr570 respectively. The activated CTKD then auto-phosphorylates 
RSK 1-3 in the HM at amino acids Ser380, Ser386 and Ser377 respectively. The HM 
phosphorylation is essential for activation of the RSKs. This phosphorylation creates a 
docking site that facilitates the interaction between the HM and PDK1 via the PDK1 
interacting fragment (PIF). This docking site is most likely created by conformational 
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changes induced by the HM phosphorylation in conjunction with the previous CTKD 
phosphorylation, which exposes previously concealed amino acids. This is supported by 
experimental data in unstimulated cells, where a RSK HM/N-terminus construct was 
phosphorylated but a RSK HM/C-terminus construct and full length RSK were not 
phosphorylated, suggesting that unphosphorylated CTKD conceals the HM (Frödin et al. 
2000). Alongside the HM phosphorylation two further phosphorylations occur in the linker 
region in the TM for RSK 1-3 at amino acids (Thr359, Ser363), (Thr365, Ser369) and 
(Thr356, Ser360) respectively. The kinase responsible for these phosphorylations has been 
shown to be a MAPK due to the specific recognition sequences (Dalby et al. 1998). Due to 
previous ERK involvement in RSK activation it is hypothesised to be ERK, but the exact 
mechanism is still to be elucidated. The purpose of these two phosphorylations is to 
enhance the interaction of HM and PDK1, by assisting C-terminal conformational changes 
(Pearce et al. 2010). Once PDK1 is recruited to RSK 1-3, its kinase activity is stimulated by 
the phosphorylated HM (most likely by inducing conformational changes in PDK1 that 
stimulate autophosphorylation) (Frödin et al. 2000), which is stabilised by the phosphorylated 
TM. PDK1 is then able to phosphorylate the NTKD of RSK 1-3 at amino acids Ser221, 
Ser227, Ser218 respectively. PDK1 then dissociates in a fully active with the ability to 
phosphorylate other substrates. The now catalytically active NTKD auto-phosphorylates the 
C-terminus just outside of the D-domain in RSK1 and RSK2 at amino acids Ser732 and 
Ser715 respectively. These phosphorylations create an auto-inhibitory effect reducing the 
affinity to ERK and producing a negative feeback loop for RSK activation (Romeo et al. 
2012). RSK3 does not have this phosphorylation which could be linked to ERK remaining 
bound for longer than RSK1/2 (Roux et al. 2003). The RSKs are then inactivated by 
phosphatases and return to an inactive state (Romeo et al. 2012). 
RSK4 activation mechanism is largely uncharacterised, but initial evidences suggest it differs 
from RSK1-3 mechanism. Inactive ERK is found in a pre-formed complex with inactive 
RSK4. ERK is stimulated and phosphorylates RSK4 on the CTKD at amino acid Thr581. The 
CTKD then auto-phosphorylates the HM at amino acid Ser389 while ERK phosphorylates 
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the TM only in one position (in contrast to two positions with RSK1-3) at amino acid Ser372. 
The NTKD is phosphorylated in a PDK1-independent manner most likely by an 
autophosphorylation event at amino acid Ser232 (Dümmler et al. 2005). The NTKD then 
autophosphorylates the C-terminal just outside the D-domain at amino acid Ser742 to create 
an auto inhibitory effect, reducing affinity to ERK. The significant difference with RSK4 to the 
other RSK isoforms is that it found constitutively active across most cells even in serum-
starved cells. The serum starved cells are not stimulated by growth factor meaning the 
MAPK pathway is inactive, thus RSK4 activation is growth factor independent. This is 
because the expression of RSK4 is so low that the basal concentrations of ERK are 
sufficient enough to cause maximal phosphorylation of ERK sites. This, in combination with 
the PDK1-independent NTKD phosphorylation, allows activation of RSK4 independently of 
growth factor (Dümmler et al. 2005). The general mechanism of action which was described 
in-depth previously and the cellular outcomes of RSK activation have been illustrated (Figure 
1.3.1).  
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Figure 1.3.1 – Schematic representation of MAPK signalling pathway. The RSKs are 
activated by the activation of the MAPK pathway via a phosphorylation cascade. The RSKs 
can then translocate to the nucleus and phosphorylate Transcription factors and/or Co-
regulators to influence the transcriptional program resulting in production in mRNA. 
Additionally, the RSKs phosphorylate several cytosolic proteins which regulate cellular 
processes like the cell cycle, protein translation, apoptosis and cell motility.  
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1.4 - Cellular Roles 
The RSKs are the most downstream effectors of the MAPK pathway. The activation of these 
proteins allows phosphorylation of a range of substrates, which leads to changes in several 
cellular processes. The RSKs have been shown to have roles in transcription and translation 
regulation, cell cycle and proliferation, cell survival, and cell migration (Figure 1.3.1). 
 
1.4.1 - Regulation of Transcription 
In response to mitogenic signal and translocation to the nucleus, RSKs phosphorylate 
specific transcription factors, which result in the transcription of the Immediate Early Genes 
(IEGs). RSK2 phosphorylates cAMP Responsive Element Binding protein (CREB) in 
response to epidermal growth factor (EGF) causing binding to its recognition site within the 
C-fos promoter and transcription of IEG product (Bruning et al. 2000). RSK2 also 
phosphorylates Serum Response Factor (SRF) at Ser103 increasing it affinity for the Serum 
Response Element (SRE) within the promoter of C-fos leading to its transcription (Rivera et 
al. 1993). RSKs have also been shown to directly phosphorylate the IEG products. In fact, 
RSK1/2 phosphorylates C-fos at Ser326 cooperatively with ERK which phosphorylates C-fos 
at Ser374 (Chen et al. 1993). These phosphorylations stabilise C-fos and increase its 
transactivation activity (Chen et al. 1996). The IEGs act as molecular sensors, which allows 
for differentiation between transient and sustained mitogenic signal. The initial signal may be 
long enough for RSK/ERK to phosphorylate transcription factors such as SRF or CREB to 
produce IEG products such as C-fos but if the signal is not sustained ERK/RSK are 
inactivated and are unable to phosphorylate C-fos before it is degraded. A sustained signal 
causes ERK/RSK to remain active, phosphorylate the IEG products such as C-fos, which 
stabilises the protein. Additionally, these phosphorylations create new sites within C-fos 
which allow further phosphorylation events to occur (Murphy et al. 2002). C-fos then 
positively regulates the expression of Cyclin D-1, which is necessary for G1/S phase 
transition. 
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The RSKs regulate transcription of other important cellular processes via different 
transcription factors. For example, RSK1/2 cooperatively phosphorylates Transcription 
Initiation Factor - IA (TIF-IA) with ERK. The RSK phosphorylation of Ser649 precedes ERK 
phosphorylation of Ser633 which then leads to initiation of transcription of RNA polymerase I 
(Zhao et al. 2003), the polymerase necessary for RNA synthesis. RSK1/2 also 
phosphorylate CREB at Ser133 in response to Brain Derived Neurotrophic Factor (BDNF) 
and growth hormones. CREB then binds to promoters of CREB responsive genes and 
transcribes pro-survival gene bcl-2 which promotes cell survival of neurons (Bonni et al. 
1999). Similarly, RSK1/2 also phosphorylate the transcription factor FRA1 at Ser252 which 
controls the expression of cell motility genes these, phosphorylations also stabilise the FRA1 
protein in order to sustain expression of its target genes (Doehn et al. 2009). RSK substrate 
phosphorylation can even induce degradation of the target. For example, it has been shown 
that RSK1 can form a complex with IkBα/β (inhibitors of NF-kB) and Nuclear Factor kappa-
light-chain-enhancer of activated B cells (NFkB). Once stimulated RSK1 phosphorylates 
IkBα on unknown residues and IkBβ on Ser19 and Ser23 causing ubiquitination and 
degradation of the proteins. This removes the previous inhibition of NFkB. NF-kB can then 
induce expression of its target genes to combat inflammation (Xu et al. 2006). Similarly, 
RSK1 phosphorylates the transcription factor Myc inhibitor Mitotic Arrest-Deficient protein 1 
(MAD1) on Ser145. This phosphorylation causes the ubiquitination and degradation of 
MAD1 leading to enhanced Myc transcription of proliferative genes (Zhu et al. 2008). 
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1.4.2 - Regulation of Protein Translation 
RSKs were initially thought to be the primary kinases for Ribosomal Protein S6 kinase 
(RPS6) a component of the ribosomal 40S subunit, (Erikson & Maller 1986). It was later 
shown that ribosomal S6 Kinase 1 and 2 (S6K1/2) are the primary kinases for RPS6, which 
phosphorylate five clustered serines at the C-terminus of RPS6 in comparison to RSK1/2, 
which only phosphorylate RPS6 on Ser235 and Ser236. These RSK1/2 mediated 
phosphorylations are in response to MAPK pathway stimulation via several different stimuli 
and occur in a mTORC independent manner. Once RPS6 is phosphorylated at these 
specific residues the affinity of RPS6 for the 7-methylguanosine cap complex is increased 
promoting recruitment of the translational complex, highlighting the importance of RSK1/2 in 
the formation of the preinitiation complex necessary for protein translation (Roux et al. 2007). 
As part of the preinitiation complex, there are several different eukaryotic initiation factors 
(eIFs), which recruit the ribosome to mRNA and initiate translation. The heterotrimeric 
eukaryotic Initiation Factor – 4F (eIF4F) consists of a cap binding protein eIF4E, a 
scaffolding protein eIF4G and a helicase eIF4A. RSK1/2 phosphorylates eIF4B on Ser422 in 
response to serum stimulation of the MAPK pathway, this enhances cap dependent 
translation by stimulating the helicase activity of eIF4A to unwind the structure of mRNA 
ready for translation. This translational stimulation occurs in a convergent manner, the 
MAPK pathway produces a transient signal through RSK1/2 alongside a sustained signal 
from the phosphoinositide 3 kinase (PI3K) pathway through S6K (Shahbazian et al. 2006). It 
has also been shown that RSK2 can increase protein production by phosphorylating the 
Glycogen Synthase Kinase 3β (GSK3β) at Ser9, which inhibit its kinase activity and 
alleviates its inhibition on eIF2B, resulting in increased translation (Sutherland et al. 1993). 
RSKs are also implicated in regulation of protein synthesis by regulating mTOR, the master 
regulator of protein synthesis, which in humans exists in two complexes, mTORC1 and 
mTORC2. Tuberous sclerosis complex 2 (TSC2) is a complex formed of tuberin and 
hamartin, which inhibits mTOR signalling. RSK1/2 phosphorylates TSC2 at Ser1798 and 
Ser1799, key regulatory sites, removing the inhibition invoked by its Guanine nucleotide-
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Activating Protein (GAP) activity thus allowing mTOR signalling via S6K1, resulting in 
increased protein translation (Roux et al. 2004). RSKs can also interact directly with mTOR 
via phosphorylation of Regulatory Associated Protein of mTOR (RAPTOR), an important 
mTOR scaffolding protein. RSK1/2 were found to phosphorylate RAPTOR on three residues 
Ser719, Ser721 and Ser722, which directly stimulates the kinase activity of mTOR, which in 
turn phosphorylates S6K2. Interestingly, there are significant variances with these three 
phosphorylation sites: Ser721 is a classical recognition phosphorylation site of RSK1/2; 
Ser719 has the minimal consensus sequence of a RSK phosphorylation site; while Ser722 is 
located +1 position of the classical recognition sequence for RSKs (Carrière et al. 2008).  
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1.4.3 - Regulation of Cell cycle and Cell Proliferation 
RSKs can regulate cell proliferation via regulation of cell cycle components. P27Kip1 is a 
Cyclin Dependent Kinase (CDK) inhibitor that sequesters and inactivates cyclin A/E – CDK2 
complexes, and its own activity is regulated by concentration and cellular localisation. 
RSK1/2 phosphorylate P27Kip1 on Thr198, stimulating its binding to 14-3-3 scaffolding 
proteins. Once bound to the scaffolding proteins P27Kip1 remains localised to the cytoplasm 
preventing translocation to the nucleus and sequestering of cyclin A/E, thus allowing A/E – 
CDK2 complexes to form and G1 / S phase transition to occur (Fujita et al. 2003). In addition 
to regulation of G1/S phase, RSKs have been shown to regulate the transition from G2 to 
Meiosis in oocytes, which are naturally arrested in late G2 phase awaiting progesterone 
stimulation for transition. Once stimulated with progesterone, transition into the M phase 
begins and a kinase, Mos, is synthesised and activates the MAPK pathway. RSK2 then 
phosphorylates Myt1. Cell Division Cycle 2 kinase (CDC2), a CDK, is responsible for this 
transition in meiosis, but is normally inhibited by Myt1. Phosphorylation by RSK2 on Myt1 
attenuates inhibition on CDC2 allowing cell cycle progression (Nebreda & Ferby 2000). In 
addition, RSK2 aids in activation of CDC2 by phosphorylating CDC25C an enzyme involved 
in activated the CDC2/ cyclin B complex (Wang et al. 2010). Furthermore, RSK1/2 
phosphorylates the Anaphase Promoting Complex (APC) inhibitor, Bub1 kinase, causing 
metaphase II arrest (Schwab et al. 2001). Additionally, RSK1/2 phosphorylate early mitotic 
inhibitor 2 (Emi2) another APC inhibitor, promoting its association with a phosphatase which 
removes all phosphorylations and activates the protein, allowing its inhibition of the APC and 
continued anaphase arrest (Nishiyama et al. 2007). RSK4 has been shown to cause G0 – G1 
cell cycle arrest. This occurs by RSK4 causing hypophosphorylation of pRB and increased 
expression of p21 but by an unknown mechanism (Thakur et al. 2008). RSK3 was shown to 
reduce proliferation in cancer cells by causing cell cycle arrest in G1 phase by an unknown 
mechanism (Cargnello & Roux 2011).  
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1.4.4 - Cell Motility  
RSK1/2 were first shown to be involved in cell motility by phosphorylating cytoskeleton 
protein filamin A on Ser2152 in response to growth factors. After phosphorylation filamin A 
was shown to migrate at a significant rate and this phosphorylation is essential for 
membrane ruffling (Woo et al. 2004). RSK1/2 also regulate a range of motility functions in 
epithelial cells; cell scattering, wound healing, cell multilayering, chemotaxis, 3D organoid to 
2D migration and 3D ECM invasion. RSK1/2 were also found to participate in an autocrine 
feedback loop (Doehn et al. 2009). Hemidemisomes (HDs) are junctional complexes that aid 
adhesion of epithelial cells to basal membrane. The hemidemisomes are formed of intergrin 
α6β4, plectin, pemphigoid antigens and tetraspanin CD151. Following growth factor 
stimulation of keratinocytes RSK1/2 phosphorylate the β4 subunit of intergrin at Ser1356 
and Ser1364 which hinders the interaction between the β4 subunit and plectin causing a 
reduction in HDs and an increase in cell motility due to a decrease in strength of cell 
adhesion (Frijns et al. 2010).  
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1.4.5 - Cell Survival 
The RSKs also have roles in the regulation of cell survival, most of which occur by post-
translational modifications and result in inhibition of a pro-apoptotic protein saving the cells 
from apoptosis, cell death programme. RSK1/2 phosphorylates Bcl-2 Associated Death 
protein (BAD) on Ser112 (Bonni et al. 1999) which causes BAD previous dimerization with 
Bcl-xl to become reversed. Once the Bcl-xl is free and no longer inhibited by BAD it can 
carry out its pro-survival function. The phosphorylated BAD binds to 14-3-3 scaffolding 
proteins sequestering it from further inhibition of Bcl-xl (Shimamura et al. 2000). In a similar 
manner RSK1/2 phosphorylates Death Associated Protein Kinase (DAPK) on Ser289 
causing inhibition of its pro-apoptotic activity and a significant reduction in cell death (Anjum 
et al. 2005). It has also been shown that RSK1 phosphorylates Ccaat/Enhancer Binding 
Proteinβ (C/EBPβ) on Thr217. This causes the creation of a functional XEXD caspase 
substrate/inhibitor box due which binds to and inhibits the caspases 1 and 8 preventing them 
from activating effector procaspases that execute the apoptosis programme, allowing 
survival of the stellate cells (Buck et al. 2001). 
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1.5 - RSKs and Cancer  
In the last 10 years, the RSKs have been connected to cancer mostly due to their 
involvement in key cellular processes. These processes in cancer often become 
dysregulated due to abnormal expression or activity of RSKs allowing the cancerous cells to 
uncontrollably proliferate. However, the story is complicated by the fact that different RSK 
isoforms perform different, sometime opposing, functions in different cancer types 
 
1.5.1 - Breast Cancer (BCa) 
BCa has many subsets with varying expression of different receptors. In a study focused on 
BCa with high expression of Fibroblast Growth Factor Receptor 1 (FGFR1), it was shown 
that RSK1 can regulate the proliferation in these cells to some degree by an unknown 
mechanism. This was elucidated by treating three different BCa cell lines with RSK1 inhibitor 
chloromethylketone (cmk) which caused a reduction in cell proliferation, suppressed colony 
formation and decreased survival of the FGFR1 expressing cells (Xian et al. 2009). RSK2 
have also been shown to interact with estrogen Receptor alpha (ERα) in a two-step 
mechanism, firstly RSK2 binds to the Ligand Binding Domain (LBD) between residues 326-
394 which influences the activity of the AF2 domain causes conformational change which 
exposes Ser167 for phosphorylation by RSK2 which influences the Activation Function 1 
(AF1) domain and enhances the transcriptional activity of ERα (Clark et al. 2001). This 
phosphorylation is present in hormone driven BCa and is used as a prognostic for patients to 
determine if they are suitable for endocrine therapy after relapse as it increase the chances 
of overall survival (Yamashita et al. 2008). RSK2 can also promote cell survival in BCa by 
the formation of stress granules, which reduces the translation of selective mRNAs. RSK2 
facilitates the formation of stress granules by direct interaction and sequestering of TIA-1 (an 
RNA binding protein that acts as a translational inhibitor) and PABP-1 a stress granule 
marker to form the granule. The mechanism which causes the cell survival is unknown but is 
shown by siRNA silencing of RSK2 of the BCa cells resulted in increased apoptosis 
(Eisinger-Mathason et al. 2008). RSK1/2 were also shown to phosphorylate YB1 at Ser102 
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resulting in increased expression of EGF receptor (EGFR) which in turn results in increased 
proliferative signal due to an increased amount of growth hormone receptor (Stratford et al. 
2008). RSK2 was also shown to regulate its expression of cyclin D1 in BCa, use of RSK 
inhibitors in MCF-7 cells caused a reduction in both protein and mRNA levels of cyclin D1, 
cyclin D1 itself is an oncogene promoting proliferation (Eisinger-Mathason et al. 2008). 
Differently, RSK4 acts as a tumour suppressor in BCa by causing an overall reduction in cell 
metastasis, reduction in cell proliferation. RSK4 achieves inhibition of cell metastasis most 
likely by regulation of CXCR4 and CLDN2, of which induced decreased and increased 
expression respectively. This change in expression would mediate a reduction in metastasis 
as CXCR4 specifically induces metastasis and CLDN2 is a transmembrane protein which is 
also a component of tight junctions which maintain integrity of epithelial tissues, when 
altered results in mesenchymal transition (Thakur et al. 2008).  
 
1.5.2 - Prostate Cancer (PCa) 
RSK2 regulates proliferation of prostate cancer by enhancing the expression of prostate 
specific antigen (PSA) and regulates androgen receptor mediated expression most likely by 
indirect phosphorylation (Clark et al. 2005). RSK1 has also been implicated in prostate 
cancer by phosphorylating the transcription factor Y-box Binding protein 1 (YB1), which 
increases androgen receptor (AR) transcription in response to AR degradation caused by 
androgen deprivation therapy used to induce apoptosis (Shiota et al. 2014). 
 
1.5.3 - Ovarian Cancer (OvCa) 
RSK3 has been shown to repress growth in multiple OvCa cell lines, this is further 
potentiated by overexpression of RSK3 which provided simultaneous results (Eisinger-
Mathason et al. 2010).  
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1.5.4 - Lung Cancer (LCa) 
A short interfering RNA (siRNA) study showed that RSK1 knock down in lung 
adenocarcinomas resulted in enhanced metastatic potential with an increase in cell 
migration and invasion suggesting tumour suppressor properties of RSK1 in this type of 
cancer. In the same study RSK2 and RSK4 were also investigated, in a converse manner 
these knock downs showed inhibition of cell metastasis suggesting that they are metastatic 
promoters in lung adenocarcinoma (Lara et al. 2011). In Non-Small Cell Lung Cancer 
(NSCLC) RSK1 phosphorylates BAD, as previously mentioned, and promotes cell survival 
(Hurbin et al. 2005). By an alternative mechanism RSK1/2 also promote cell survival in 
NSCLC by phosphorylating Bcl-2 Interacting Mediator of death – Extra Long (BIMEL) (one of 
three BIM splice variants). BIMEL regulates the Bcl-2 associated X protein (Bax) mediated 
apoptosis, BIMEL when phosphorylated on Ser69 interacts with F-box protein bTrCP 
causing its degradation. This degradation prevents BIMEL from stabilising Bax and BCL 
from permeabilising the mitochondrial membrane and releasing cytochrome C, which 
induces the apoptotic program. Ultimately allowing the cancerous cells to escape cancer 
therapy induced apoptosis (Dehan et al. 2009). 
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1.5.5 - Acute Myeloid Leukaemia (AML) 
AML is treated with arsenic trioxide (As2O3) to target the cancerous cells however 
chemoresistance to this treatment arises. This chemoresistance arises from activation of 
RSK1 in response to As2O3 and phosphorylation of Bad at Ser112 causing an anti-apoptotic 
signal that allows the cancerous cells to survive (Galvin et al. 2013). RSK2 is also involved in 
Leukaemia by a different mechanism; Leukaemogenic tyrosine kinases (LTKs) activate 
RSK2 in leukaemia cells to generate a myeloproliferative neoplasm signal causing 
expansion of neutrophils. The LTKs that activate RSK2 are BCR-ABL (a fusion protein) and 
FMS-like tyrosine kinase 3 (FLT3) - internal tandem duplication (ITD) mutant (FLT3-ITD). 
However in response to inhibition of RSK2, only cells expressing the FLT3-ITD showed 
increased apoptosis suggesting RSK2 is dispensable in BCR-ABL positive cells (Elf et al. 
2011). 
 
1.5.6 - Head and Neck Squamous Cell Carcinoma (HNSCC) 
In HNSCC RSK2 invokes metastasis by phosphorylating two substrates. RSK2 
phosphorylates CREB at Ser133, which most likely cause a transcriptional dependent 
signalling cascade which results in the expression of pro-metastatic genes. RSK2 also 
phosphorylates Heat Shock Protein 27 (HSP27) at Ser78 and Ser82 to regulate actin 
filaments by controlling their state of polymerisation (Kang et al. 2010).  
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1.5.7 - Melanoma 
In skin cancer (SCa) melanoma drugs such as cisplatin often cause an initial response in 
cancerous cells causing apoptosis. This occurs by activation ataxia telangiectasia mutated- 
and RAD3-related protein, which in turn phosphorylates checkpoint kinase 1 (Chk1) at 
Ser317 and Ser345 enabling its activity. Chk1 then goes onto rapidly degrade CDC25 
phosphatase leading to cell cycle arrest for DNA repair before mitosis. However, 
chemoresistance often builds up due to RSK1/2 phosphorylation of Chk1 at Ser280 inhibiting 
the protein and allowing the cells to proceed through the cell cycle and silencing of the G2 
DNA repair mechanism in tumour promoting manner (Ray-David et al. 2013). RSK1 also 
promotes cell survival in melanoma by phosphorylating BAD at Ser75 causing its inactivation 
and removal of the apoptotic signal by the previous mechanism mentioned (Eisenmann et al. 
2003). 
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1.6 - RSK Inhibitors  
As demonstrated above the RSKs are involved in a range of metabolic processes by a 
variety of mechanisms. When studying these proteins, whether to prove a function or for 
potential use as a cancer therapeutic, the use of inhibitors is essential. There are two 
different ways in which inhibitors affect the RSKs, both of which affect their kinase domains, 
by target of the CTKD or the NTKD. BI-D1870 competes for the ATP binding site of the 
NTKD in a reversible manner and is highly selective for RSKs relative to other AGC kinases, 
the IC50 is 15-30nM at ATP concentration 100µM. This inhibitor shows higher propensity to 
inhibit RSK4 out of the four isoforms but still inhibits all four isoforms significantly. SL0101 is 
another inhibitor that competes for the ATP binding site of the NTKD in a reversible manner 
but does so in a less potent manner when comparing to BI-D1870 with an IC50 of 90nM at 
ATP concentration 10µM. Fmk is another inhibitor but interacts with RSKs differently, fmk 
contains an electrophile which enables inhibition to occur via covalently linking to the RSK in 
an irreversible manner. This occurs via covalent addition of its chloromethlyketone group to 
a thiol group from a Cys residue near the ATP binding site of the CTKD. Despite inhibiting 
via a covalent modification this inhibitor is still highly selective for the RSKs with reasonable 
potency IC50 of 1.2µM. However, fmk cannot inhibit RSK3 because it possesses a 
methionine at the ‘gatekeeper’ residue of the ATP pocket which prevents the entry of fmk 
into the pocket. The different mechanism of inhibition between the two types means that BI-
D1870 and SL0101 inhibit phosphorylation of substrates of the RSKs by interacting with 
NTKD whereas fmk inhibits activation of the CTKD thus maximal activation of the proteins 
(Nguyen 2008). These inhibitors are now considered the traditional inhibitors of the RSKs, 
however in recent years new and more potent inhibitors have been designed. Two next 
generation inhibitors, LJH685 and LJI308, inhibit and bind to the RSKs via the NTKD ATP 
site. Both inhibitors have high selectivity and potency for the RSKs and inhibit in vivo and in 
vitro with an IC50 of 0.2-0.3µM/L. Furthermore, the mechanism of inhibition is unusual by 
forming a non-polar conformation which aids in its selectivity (Aronchik et al. 2014).  
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1.7 - Steroid Receptor Structure and Activation  
1.7.1 - Structure 
Steroid Receptors (SRs) are transcription factors which bind to their cognate ligand and 
additional regulators (cofactors) to control gene expression. The primary ligand for each 
receptor is testosterone/dihydrotestosterone (DHT) for the Androgen Receptor (AR), 17β-
estradiol (E2) for the Estrogen Receptor alpha (ERα), cortisol for the Glucocorticoid 
Receptor (GR), progesterone for the Progesterone Receptor (PR) and aldosterone for the 
Mineralocorticoid Receptor (MCR). SRs are a subfamily of the superfamily Nuclear 
Receptors (NRs). They share this superfamily with three other subfamilies; 
thyroid/retinoid/vitamin D receptors, peroxisome proliferator activated receptors and the 
orphan receptors. 
 
All NRs have a degree of sequence homology and share a general structure (Figure 
1.7.1.1). This shared structure consists of two main features; the DNA Binding Domain 
(DBD) which is positioned roughly in the middle of the protein and the Ligand Binding 
Domain (LBD) which is positioned towards the C-terminus. These two domains are 
connected by a hinge region (Kumar & Thompson 1999). The DBD is composed of a 
conserved 66 amino acid central core followed immediately by a short unconserved 
extension into the hinge region. The conformation of the DBD creates two alpha helices and 
two zinc binding groups. One of the alpha helices is responsible for DNA recognition via the 
major groove, whilst the second is essential for hetero/homodimerisation (Rastinejad 2001). 
Additionally, the DBD is responsible for the selectivity of which DNA response element it 
binds to. Properties like N-terminal flexibility, length of the hinge region and amino acid 
sequence determines positioning on DNA and in turn selectivity. Furthermore, the extension 
into the hinge region stabilises DNA binding by interacting with the minor groove of DNA 
(Helsen & Claessens 2014). 
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The LBD is composed of a three layered alpha helical structure consisting of 12 α-helices 
(H1-H12), forming an ‘α-helical sandwich’. Ligand binding to the LBD causes a 
conformational change which dictates which coregulators will be recruited, co-activators or 
co-repressors (co-regulatory proteins that either enhance or repress receptor activity), thus 
whether the protein is transcriptionally active or inactive. The conformational changes from 
ligand binding creates a hydrophobic surface for coregulators to bind (Greschik et al. 2002).  
 
NRs also have two Activation Functions: (AF) AF-1 and AF-2. AF-1 is located inside the 
highly flexible N-terminus, this domain varies in length and sequence and is recognised by 
co-regulators. AF-2 is located to the LBD where it is induced by ligand binding to create the 
interaction surface for co-regulators. In addition to their structural features the SRs possess 
positions in their structure which allow for post-translation modifications. These modifications 
can also influence their transcriptional activity (Lavery & Mcewan 2005).  
 
 
 
Figure 1.7.1.1 - Schematic representation of SR functional domains. The activation 
function 1 (AF-1) is present in the N-terminus of the SR proceeded by the DNA binding 
domain (DBD), the DBD extends into the hinge region which proceeds into the Ligand 
binding domain (LBD) which contains the activation function 2 (AF-2) followed by an 
unstructured C-terminus.    
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1.7.2 - Mechanisms of action 
 
1.7.2.1 - Classical steroid receptor signalling 
This classical method of SR activation involves the binding of hormone to intracellular SRs.  
Signalling is initiated when the relevant hormone, diffusing through the phospholipid bilayer, 
bind to the receptor. Hormones can diffuse across the cell membrane as they are small 
lipophilic molecules. The hormone then comes into proximity with the SR usually in the 
cytoplasm and causes an allosteric change due to its chemical structure. The allosteric 
change occurs via the H12 α-helix. The H12 helix switches from a previous dynamic state 
becomes fixed in one position, closing the ligand binding pocket and further stabilising the 
ligand (Nagy & Schwabe 2004). The new positioning of H12 helix facilitates AF-2 function 
and allows co-activators to interact with the newly formed coactivator interaction groove 
(Rastinejad et al. 2013). Co-activators interact with this groove via LXXLL (L represents 
leucine and X represents any amino acid) motifs. The LXXLL motifs interact with the SR via 
a hydrophobic cleft formed from H3, H4 and H12 helices. The SR is now capable to interact 
with DNA, dependent on the SR they translocate to the nucleus if not already present there 
(Gronemeyer et al. 2004). Once in proximity of DNA one of the zinc-finger like modules of 
the DBD interacts with the major groove of DNA. This is the recognition helix which interacts 
with hexamer response elements (HREs) via specific DNA half sites (Schwabe et al. 1993). 
AR, GR, PR and MR recognise 5’-AGGACA-3’ where as ERα recognises 5’-AGGTCA-3’ half 
sites. The half sites are found by utilising a series of hydrophilic residues which read the 
DNA sequence until recognition of the specific response element. As an added layer of 
selectivity to ensure correct recognition, in a DNA-dependent manner the SRs cooperatively 
form homodimers to account for orientation and space between half sites. The SRs form 
these homodimers via the second zinc finger like module present in the DBD (Roemer et al. 
2006). 
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Figure 1.7.2.1.1 – Schematic representation of SR signalling pathway.  
Ligand diffuses across the phospho-lipid bilayer, binds to its SR which causes 
homodimerization and translocation to the nucleus. In the nucleus SR bind to are influenced 
by Co-regulators to determine the transcriptional program. mRNA is produced and translated 
into a polypeptide which then folds into the SR regulated protein which then carries out its 
relative function. The SR regulate proteins then regulate a variety of cellular processes such 
as: neuro-protection, sexual development, metabolism, immune system, gestation, 
inflammatory response, cardiovascular system and bone density.   
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1.7.2.2 - Non-classical steroid receptor signalling 
The non-classical mechanism of action occurs via the activation of membrane-bound SRs. 
Activation via this mechanism can cause a range of signalling events which can then alter 
other signalling pathways. The most frequently activated pathways are the MAPK pathway, 
the PI3-AKt pathway and second messengers such as IP3 and cAMP can also be activated 
(Lösel & Wehling 2003). The mechanisms non-classical signalling seen across all the SRs is 
not as transferable as the classical activation, but examples can be shown. For example, 
activation of membrane bound ERα leads to activation of G-protein coupled receptors 
(GPCRs) which in turn leads to the activation of PLC and the production of DAG and IP3. 
These molecules then cause an influx of Ca2+ and the activation of PKC (Chaudhri et al. 
2014). PKC then activates downstream MAPKs which influence gene expression, promoting 
proliferation. Additionally, E2 activation can induce anti-apoptotic effects and promote cell 
survival via PI3K. Activation of PLD at the membrane leads to the production of LPA which in 
turn activates PI3K. PI3K then stops the caspase cascade which inhibits apoptosis 
(Schwartz et al. 2016). Similarly, treatment with progesterone was shown to affect the cell 
cycle by causing cell cycle arrest in G1. This was done via the MAPK pathway which 
targeted cyclin D1. Loss of cyclins A/B and reduction in cyclin D1, D3 and E were also seen 
(Garg et al. 2017). Within one minute of treatment with androgen, cells show a Ca2+ influx 
which leads to cytoskeleton rearrangements and PSA expression secretion within ten 
minutes. This occurs rapidly in comparison to classical signalling (Rahman & Christian 
2007).  
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1.8 - Steroid Receptor Expression and Function 
 
The SRs are widely expressed throughout the body, as they regulate gene transcription they 
serve many physiological functions. However, the SRs have different expression profiles and 
transcribe different genes resulting in varied effects and phenotypes across tissues. 
 
1.8.1 - Androgen Receptor (AR) 
The genes transcribed by the AR determines the outcome of that cell, however this varies 
dependent on tissue and conditions. Immunohistochemistry has shown the AR is expressed 
primarily in the male and female sexual organs; the vagina, cervix, ovaries and breast in 
women; accessory sex organs, the testes and the skeletal muscles surrounding the male 
reproductive organs. Additionally AR was detected in sweat glands (Ruizeveld De Winter et 
al. 1991). Within the primary reproductive organs of men, AR function is mainly related to the 
development and maintenance of these organs. However, due to expression and gene 
regulation in several tissues, a distinct function of the AR cannot be applied. Several studies 
have used genetically modified mice to produce a tissue specific global Knock Out (KO) 
model to investigate key changes in phenotype when AR is diminished (Davey & Grossmann 
2016). It yielded substantial results across several tissues and highlights the widespread 
expression and function of AR, despite being secondary expression sites. In the AR 
expressing non-reproductive organs in males, AR regulated transcription contributes to; 
bone density (Yeh et al. 2002), sexual drive and aggression (Sato et al. 2004), development 
of the heart (Ikeda et al. 2005), metabolism homeostasis (Rana et al. 2011), muscle 
formation (MacLean et al. 2008) and regulation of the haemopoietic immune system (Lai et 
al. 2012). The same principle was applied to female mice but was limited to the reproductive 
organs. AR transcription was shown to contribute to folliculogenesis, mammary gland 
development, and uterine morphology and development (Walters et al. 2009). 
 
The AR receptor facilitates the expression of numerous Androgen Response Elements 
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(AREs), where the AR binds to and facilitates transcription, throughout the genome 
(DePrimo et al. 2002). The composition and context of these sites differ between different 
genes allowing AR to navigate several different regulatory functions within one nucleus. 
Expression profiling analysis on prostate cells showed 205 Androgen Responsive Genes 
(ARGs) and chromatin immunoprecipitation (Chip) validated 524 AREs. Two thirds of the 
ARE sites were within 50kb of an ARG transcription start site. However, most ARGs were 
linked to more than one ARE. An additional level regulation was also present, gene clusters 
some of which consisted of 13 AREs and 12 ARGs. Furthermore, many AREs were shown 
to be adjacent to other binding motifs of other transcriptional regulators (Bolton et al. 2007). 
This highlights the complexity AR transcriptional regulation, but this is further regulated by 
the recruitment of nuclear co-regulators and transcription factors. In the absence of ligand, 
the AR resides in the cytoplasm until ligand binding. Prior to this, the Hsp90 complex is 
bound to AR in the cytoplasm along with other chaperones to increase AR stability. The 
BAG-1L component was shown to enhance transactivation of AF-2 by aiding in the correct 
folding of the AR when ligand binds exposing its Nuclear Localisation Sequence (NLS) 
(Froesch et al. 1998). Phosphorylation of the transcription factor STAT3 allowed its 
interaction with the AR and enhancement of its transcriptional activity (Chen et al. 2000).   
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1.8.2 – The Glucocorticoid Receptor (GR) 
The GR is expressed in almost all tissues in the body and primarily resides in the cytoplasm. 
Despite being almost ubiquitously expressed there are two primary functions of the GR; 
metabolic homeostasis and response to stress through the immune system for example, 
inflammation. These processes extend across the whole body and are facilitated through 
hormone communication, but the mechanism varies dependent on tissue type. The 
production of glucocorticoids themselves are under control of a negative feedback loop by 
the hypothalamo-pituitary-adrenal axis (HPA) (Kudielka & Kirschbaum 2005). The 
hypothalamus is activated and secretes vasopressin (VA) and corticotropin releasing factor 
(CRF), which is controlled by the amygdala and hippocampus. These hormones then 
stimulate the anterior pituitary gland which secretes adrenocorticotropic hormone (ACTH) 
which in turn stimulates the adrenal cortex to produce glucocorticoids (GCs). The GCs then 
complete the negative feedback loop by inhibiting the production of ACTH and CRF. In 
response to stress, physical or mental (for example danger), the HPA axis becomes 
activated and increases the production of GCs which executes a variety of tissue specific 
effects. For example, GC’s cause the mobilisation of energy sources through GR mediated 
transcription of gluconeogenic genes. The enzymes phosphoenolpyruvate carboxy kinase, 
glucose-6-pase, serine dehydratase and tyrosine amino-transferase are transcribed in 
hepatocytes, lipolysis is increased in the adipocytes and glucose uptake is reduced in 
peripheral tissues resulting in large scale relocation of glucose (Tronche et al. 1998).  
 
The GR regulates inflammatory effects through the immune system. The immune system 
has two layers of defence. The initial response comes from the innate immune system which 
utilises the invariant pattern recognition receptors on the surface of macrophages, dendritic 
cells and other specialised cells. Through signalling pathways, the adaptive immune system 
becomes active and recruits T and B lymphocytes, which causes inflammation at the site. It 
is here the GR regulates inflammation at a cellular and transcriptional level (Oakley & 
Cidlowski 2011). On a cellular level the GR can cause apoptosis of the lymphocytes and 
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other specialised cells to reduce inflammation. The most common way GR regulates 
inflammation through transcription is by regulating the expression of Activating Protein-1 
(AP-1) and Nuclear Factor Kappa-light-chain-enhancer of activated B cells (NFkB). AP-1 is a 
key regulator of the inflammatory response, acting as a homo/heterodimer of leucine zipper 
transcription factors of which there are many; the Fos family, the Jun family, the ATF family 
and the MAF family. However, the most common form in response to downstream cytokine 
signalling caused by inflammation is the Fos/c-Jun heterodimer. The dimer formation is 
dependent on the phosphorylation of c-Jun by c-Jun N-terminal Kinase (JNK). The AP-1 
complex then regulates the transcription of several pro-inflammatory genes via AP-1 
response elements (Cruz-Topete & Cidlowski 2014). The GR interferes with AP-1 by three 
different mechanisms; (i) GR can be tethered to the c-Jun subunit which represses the 
activity of AP-1 thus inhibits pro-inflammatory gene transcription; (ii) GR binds to 
Glucocorticoid Responsive Element (GRE) whilst simultaneously tethering c-Jun thus 
repressing transcriptional activity of AP-1; (iii) GR induces transcription of MKP-1, a 
phosphatase which can dephosphorylate JNK thus removing AP-1 activation. Under normal 
conditions NFkB is retained in the cytoplasm due to the inhibitor IkB (Smith & Cidlowski 
2010). Under inflammatory conditions the IkB kinase (IKK) is activated and phosphorylates 
IkB which causes its degradation. The degradation of IkB removes its previous inhibition of 
NFkB and allows its translocation to the nucleus. Once in the nucleus NFkB can bind to its 
response elements and induce transcription of several pro-inflammatory genes. The 
mechanism in which the GR represses the transcriptional activity of NFkB is unknown but it 
thought to be similar to that of AP-1 (Busillo & Cidlowski 2013). Following the downregulation 
of inflammation there is a resolution stage, GR regulates transcription of genes which 
promote phagocytosis of apoptotic cells and cell debris in macrophages and monocytes. 
Additionally, GR induces transcription of the anti-inflammatory cytokines Transforming 
Growth Factor β (TGFβ) and Interleukin-10 (IL-10). Furthermore GR induces the 
transcription of lipoxin A4 receptor, a pro-resolving factor, to sensitise the surrounding cells 
to stimulation of resolving factors (Cain & Cidlowski 2017).  
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1.8.3 – Estrogen Receptor α 
The ERα is primarily expressed in the reproductive organs and its primary function is the 
development and maintenance of those organs. However, ERα is also expressed in most 
tissue types around the body and regulates various functions, including metabolic, 
cardiovascular, musculoskeletal, immune and in the nervous system. The role of ERα in 
metabolic homeostasis has been shown through KO models in mice and rats. The ERα KO 
mice showed increased adiposity, primarily mediated through the reduction in energy 
expenditure and an increase in food intake (Brown & Clegg 2010). This coincided with 
another study which used viral RNA interference vectors to reduce ERα expression in a 
specific region of the brain, the Ventromedial Nucleus of the Hypothalamus (VMH), which 
had a subsequent effect upon body weight, but no mechanism was elucidated (Musatov et 
al. 2007). More recent studies have identified some components of metabolic homeostasis 
regulated by the ERα. Through the independent expression of intracellular and extracellular 
ERα, it was shown that of both were necessary to suppress visceral fat development. Mice 
which lacked either localised ERα showed increased visceral fat retention and weight gain 
(Pedram et al. 2016).  
 
ERα has been shown to regulate several components of the immune system. For example, 
ERα was shown to induce the expression of Unc93b1, an endoplasmic reticulum membrane 
protein which regulates the trafficking of Toll Like Receptors (TLRs). TLRs are key 
components of the innate immune system recognising foreign entities and are expressed on 
the membranes of monocytes (Panchanathan et al. 2013). ERα was also shown to regulate 
the expression of the cytokine IL-23R in response to TLR stimulation from external stimuli in 
dendritic cells and macrophages (Cunningham et al. 2012).  ERα has also been shown to 
repress NFkB transcriptional activity by displacing its co-activator CBP at the MCP1 
promoter. The ERα further regulates the transcriptional activity of NFkB via different 
mechanisms and also regulates AP-1 by similar mechanisms to the GR (Kovats 2015).  
 
42 
 
ERα was also shown to have protective cardiovascular effects via regulation of gene 
expression. ERα induces the expression of the vasodilatory enzymes prostacyclin synthase, 
endothelial nitric oxide synthase and regulate genes which promote growth and repair in 
response to vascular injury (Mendlesohn & Karas 1999). Additionally, ERα regulates serum 
lipid concentrations, increasing High Density Lipoproteins (HDLs) and triglycerides, 
decreasing Low Density Lipoproteins (LDLs), therefore reducing the accumulation of lipids 
on the artery wall. Furthermore, ERα regulates expression of coagulation and fibrinolytic 
enzymes (Mendelsohn 2002). ERα was also shown to be pivotal in bone growth both 
longitudinally and radially through the expression of insulin like growth factor 1 in KO mouse 
models (Vidal 2000).  
 
ERα also exhibits neuroprotective functions. When acute injury is sustained in the brain, 
aromatase expression is stimulated to increase the levels of estradiol. Estradiol then 
stimulates ERα mediated transcription of cell survival genes and promotes neuronal survival 
(Dubal et al. 2006). Additionally, the estradiol production stimulates the astrocytes and 
microglia cells to reduce the immediate inflammatory response via ERα (Spence et al. 
2013). This is mediated through activation of the PI3K pathway which inhibits NFkB 
activation and translocation to the nucleus thus represses inflammatory gene expression 
(Arevalo et al. 2015).  
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1.8.4 – The Progesterone Receptor 
The PR is primarily expressed in the reproductive organs and serves the purpose of 
development and maintenance of these organs. The PR is additionally expressed in the 
brain, pancreas and bone. The PR is predominantly localised to the nucleus, irrelevant of 
ligand-binding status (Scarpin 2009). The PR is vital for the initiation and progression of 
pregnancy within the uterus. The PR works in combination with the other ovarian hormone 
receptor ERα to facilitate gene expression changes throughout pregnancy. The importance 
of the PR in reproduction was demonstrated through PR KO mice models, which resulted in 
fertility defects, such as follicles which rupture the ovaries and failure of embryo implantation 
and decidualisation (Lydon et al. 1995).  As early pregnancy progresses PR expression 
increases which inhibits E2 mediated proliferation of the luminal epithelium to allow for 
embryo implantation represses recruitment of leukocytes and macrophages to the uterus 
which is essential for survival of the embryo (Tibbetts et al. 1999). Furthermore, during the 
implantation stage of pregnancy, PR was shown to be responsible for the expression of the 
Indian hedgehog (Ihh) gene, a signalling pathway molecule which promotes the correct 
development of skeletal, vascular and gastrointestinal tract systems (Dyer et al. 2001). The 
PR also induces the expression of COUP-TFII, which in combination with Ihh is essential for 
implantation through paracrine signalling and progression to decidualisation but is also 
essential for cell differentiation and tissue development (Kurihara et al. 2007). 
 
The PR has been shown to play an important regulatory role in neuroprotection. In response 
to Traumatic Brain Injury (TBI) the body tries to protect the brain by invoking inflammation, 
swelling (edema) and delayed neuronal death, however TBI remains the leading injury 
related cause of death and severe disability. By an unknown mechanism, the PR was shown 
to mediate a reduction in vasogenic and cytotoxic edema (Wright et al. 2001). Additionally, 
PR mediates a reduction in lipid peroxidation to approximately 1/3 of its levels in the 
absence of ligand. Lipid peroxidation is a major contributor to secondary damage of the 
Blood Brain Barrier (BBB) after TBI, thus a reduction in this process reduces damage (Roof 
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& Hoffman 1997). Furthermore, the PR was shown to enhance the expression of superoxide 
dismutase (SOD), an antioxidant enzyme which removes harmful reactive oxygen species, 
stabilising the BBB and in turn promoting cell survival following TBI (Moorthy et al. 2005). 
The PR has been shown to promote cell survival in response to TBI by regulating the 
immune system via repression of cytokines Interleukin 1β (IL-1β) and Tumour Necrosis 
Factor α (TNFα). The PR was also demonstrated to inhibit apoptosis via its signalling 
components cytochrome C, caspase-3 and B Cell Lymphoma-2 (BCL-2) and upregulation of 
antiapoptotic proteins such as ERK (Wei & Xiao 2013). In a similar way PR was shown to 
inhibit the β-amyloid peptide 25-35 (Aβ) induced apoptosis program pathway in Alzheimer 
mice models. This was done synergistically by PR repression on the Aβ induced expression 
of JNK, the upstream kinase of the Aβ induced apoptosis program, and through non-
classical inhibition of the apoptotic pathway (Qin et al. 2015). These findings can be further 
potentiated by the results of a genomic study which additionally implicated the PR with 
regards to TBI. This study was run over an extended 7 day period, in contrast to similar 
studies, and showed continued low dosage of progesterone resulted in the differential 
expression of 551 genes compared to vehicle. These genes were associated with increased 
proliferation, immune response, anti-apoptosis and blood vessel remodelling (Anderson et 
al. 2011). 
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1.8.5 – The Mineralocorticoid Receptor 
The Mineralocorticoid Receptor (MCR), like the other SRs, is expressed across most of the 
body and resides primarily in the cytoplasm. When first discovered, functions of the MCR 
were thought to be almost exclusive to polarised epithelial tissues like the kidneys and the 
colon where it regulated salt balance and water homeostasis (Viengchareun 2007). The 
MCR was shown to induce transcription of ionic transporters of the cell membrane, which 
are responsible for the unidirectional transport of sodium from the lumen to the interstitium. 
The MCR expresses the amiloride-sensitive Epithelial Na Channel (ENaC) subunits (Rossier 
et al. 2002), the basolateral Na+/K+ - ATPase pump subunits (Horisberger et al. 1991) and 
the pump regulatory protein Channel Inducing Factor (CHIF) (Brennan & Fuller 1999). 
Additionally, the MCR also induces transcription of the Serum and Glucocorticoid receptor 
Kinase-1 (SGK1) which phosphorylates ubiquitin ligase Nedd4-2. This inhibits the binding of 
Nedd4-2 to ENaC which promotes its degradation by the proteasome, thus allowing a pool of 
channels to reach the membrane and facilitate transport (Bhargava et al. 2001) 
 
The MCR exhibits regulation within the brain, MCR transcription was able to rescue cells 
from GR induced apoptosis in hippocampal neurons (Crochemore et al. 2005). The 
mechanism of apoptosis inhibition was shown to be through the activation function in the 
NTD of the MCR. When the MCR is introduced into Glucocorticoid sensitive pre-B lymphoma 
cell line 697, the cells exhibit a dramatic change in the expression profile. Increases in 
expression of BCL-2 and Bfl-1 and reductions in expression of BAX and BID occur. This 
happens because the MCR-NTD directly interacts with the GR, altering its transcriptional 
activity thus causes attenuation of the apoptotic program and caspase formation (Planey et 
al. 2002). The significance of MCR in the brain is further potentiated by a genomic study 
which used Serial Analysis of Gene Expression (SAGE) to determine the hippocampal 
genes regulated by GR and/or MCR in response to adrenal corticosteroids (Datson et al. 
2002). This study shows that there are 98 MCR-regulated genes and 33 genes that 
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regulated by both MCR and GR. The functions of these genes include metabolism, protein 
synthesis and signal transduction (Datson et al. 2002).  
 
The first evidence highlighting the MCR in fat regulation utilised the hibernoma cell line T37i. 
The study shows MCR induces adipogenesis by increasing expression of adipogenic 
enzymes such as lipoprotein lipase (LPL), Peroxisome Proliferator-Activated Receptor 
(PPAR) and Adipocyte-specific fatty acid binding Protein (AP2) which contribute to 
triglyceride accumulation. Together these changes in expression were indicative of very 
early stage Brown Adipose Tissue (BAT) differentiation (Penfornis et al. 2000). This is further 
potentiated with additional research which shows when MCR is inhibited by antagonist 
Drospirenone clonal expansion of preadipocytes is reduced, expression of PPAR decreases, 
differentiation is inhibited and an overall reduction in triglyceride accumulation (Caprio et al. 
2011).  
 
Obesity causes chronic low-grade inflammation increasing expression of cytokines TNFα, 
Monocyte Chemoattractant-1 (MCP-1) and Plasminogen Activator Inhibitor 1 (PAL-1). 
Additionally, in a diabetes mouse model CD-68 and leptin expression increases (in addition 
to the cytokines mentioned) paired with a decrease in expression of PPAR and adiponectin. 
These changes in gene expression were reversed following a 16-week treatment with the 
MCR antagonist eplerenone, highlighting the significant role of the MCR mediated 
transcription in obesity and diabetes (Marzolla et al. 2012).  
 
In endothelial cells of the vascular system, MCR activation has detrimental effects. MCR 
induces the expression of NADPH oxidases which are responsible for creating Reactive 
Oxygen Species (ROS) thus increases oxidative stress (Caprio et al. 2008). MCR also 
decreases expression and activity of Glucose-6-Phosphate Dehydrogenase (G6PD) which is 
a regulator of the intracellular redox state thus increases oxidative stress. MCR similarly 
reduces the expression and activity of nitric oxide synthases which are responsible for 
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combating the harmful effects of ROS thus increases oxidative stress. In combination these 
transcriptional changes lead an inhibition of vasodilation thereby increasing hypertension 
(McCurley & Jaffe 2012).  
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1.9 - Steroid Receptor Post-Translational Modifications 
As demonstrated SRs can mediate a vast array of biological functions through classical and 
non-classical signalling following ligand binding. There is an additional layer of regulation to 
this process via post-translation modifications (PTMs) by other proteins. There are five main 
PTMs that modulate SR activity: phosphorylation, ubiquitination, acetylation, and 
sumoylation.  
 
1.9.1 - Phosphorylation 
The PTM of phosphorylation has diverse effects on the SRs transcriptional activity. The AR 
has been shown to have eight phosphorylation sites, some of which modulate its 
transcriptional activity.  For example, CDK1, 5 and 9 phosphorylate the AR on Ser81, which 
increases its transcriptional activity and stabilises the protein (Koryakina et al. 2014). 
Similarly, the GR possesses eight sites and is phosphorylated by CDK5 at Ser203 and 211 
which diminished the recruitment of co-factors and repressed transcription (Kino et al. 2007). 
The ERα is phosphorylated on Ser118 and Ser167, by RSK1/2, in response to mitogen 
stimulation.  These phosphorylation events occur in the AF1 and result in an increase in 
transcriptional activity (Lannigan 2003). The PR is phosphorylated by CDK2 at Ser25, 162, 
190, 213, 400, 554, 676 and Thr430, some of these are yet to be studied but some have 
been shown to modulate transcriptional activity (Hagan et al. 2012). The MCR is 
phosphorylated by CDK5 on Ser128, Ser250 and Thr159 which negatively regulate receptor 
activity (Kino et al. 2010).  
 
1.9.2 - Ubiquitination 
The PTM of poly-ubiquitination on the SRs causes their degradation via the proteasome 
pathway. However, the specific sites that are ubiquitinated and lead to degradation have not 
been elucidated. This degradation serves a biological function; rapid degradation is needed 
to sustain and tightly regulate a transcriptional signal. This process utilises three types of 
proteins E-1 activating enzyme, E-2 conjugating enzymes and E-3 ligases (Faus & Haendler 
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2006). AR interacts with the Mouse double minute 2 homolog (Mdm2) E3 ligase and a hinge 
region phosphorylation is necessary to recruit another E3 ligase C terminus of HSC70-
Interacting Protein (CHIP), both of which leads to its degradation (Rees et al. 2006). ERα 
was shown to interact with the ubiquitin conjugase Ubc4 (Luo et al. 2005), but additionally 
Mdm2 and human papillomavirus E6-Associated Protein (E6-AP) (an E3 ligase) dependent 
on ERα Ser118 phosphorylation, which leads to its degradation (Valley et al. 2005). PR 
interacts with neural precursor cell expressed developmentally down-regulated protein 4 
(NEDD4) E3 ligase in a Ser294 phosphorylation-dependent manner which leads to its 
degradation (Qiu & Lange 2003). CHIP was shown to target the GR for proteasomal 
degradation via ubiquitination (Wang & DeFranco 2005). Like the GR, the MCR also 
interacts with CHIP which leads to its proteasomal degradation (Faresse et al. 2010).  
 
1.9.3 - Acetylation 
The PTM of acetylation regulates the affinity of co-factors to the SRs, and this is modulated 
by Histone modifying proteins. Histone Acetyltransferases (HATs) introduce acetyl groups 
whereas Histone Deactylases (HDACs) remove them. Both modifications mediate histone 
conformation and change DNA accessibility. The AR is acetylated on Lys630, 632 and 633 
by p300 and a p300/cAMP-response element-binding protein complex and mutation of these 
sites inhibits hormone induced AR transcription thus illustrating the transcriptional 
enhancement of these modifications (Fu et al. 2000). HDAC2 was shown to deacetylate the 
GR on Lys494 and 495, in response to hormone which in turn regulates NFkB signalling 
through GR-NFkB interactions (Ito et al. 2006). The ERα has several acetylation sites 
Lys266, 268, 299, 302, 303 and all are mediated by p300. Of these sites Lys266 and 268 
directly regulate DNA binding and transcriptional activity of ERα in response to hormone 
(Kim et al. 2006). The PR is acetylated at resides 638-641 within its hinge region in response 
to hormone and this causes a temporary repression of transcription by hindering 
translocation to the nucleus (Daniel et al. 2010). The MCR is deacetylated at Lys677 by 
HDAC3, this enhances the transcription of genes which contribute to hypertension. Inhibition 
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of HDAC3, causes acetylation of Lys677 and represses the expression of hypertension 
genes (Lee et al. 2013).  
 
1.9.4 - Sumoylation 
The PTM of Sumoylation covalently attaches a SUMO chain to lysine residues. This can 
have a significant effect on the fate of the protein, affecting the proteins subcellular location, 
DNA binding and transcriptional activity. Like ubiquitination, it occurs through E1 activating 
enzymes, E2 conjugating enzymes and E3 ligase enzymes (Gill 2003). The sumoylation 
sites of the AR are Lys386 and 520, which occur in a hormone dependent manner and 
approximately 10% of AR are sumoylated in steady state cells. This is mediated through the 
E3 ligase Protein Inhibitor of Activated STAT (PIAS1) and PIASxα which both show 
propensity towards the AR. Sumoylation of Lys386 reduces AR transcriptional activity 
(Kaikkonen et al. 2009). Three sumoylation sites have been identified within GR: Lys277 and 
293 which reside in the AF1 region and Lys703 which resides in the LBD. The Lys277 and 
293 sumoylations within the AF1 influence selectivity promoter site binding and increase 
transcriptional activity. However, Lys 703 had no apparent effect (Duma et al. 2006). Two 
sumoylation sites have been identified in the ERα hinge region, Lys266 and 268 which occur 
in a hormone dependent manner. PIAS1 and PIAS3 were shown to mediate the sumoylation 
events and with the addition of the E3 ligase Ubc9 they were shown to enhance the 
transcriptional activity of the ERα (Sentis et al. 2005). The PR has three sumoylation sites at 
Lys7, 388 and 531 and that modification of 7 and 531 are dependent on sumoylation of 388. 
PIAS3 was shown to mediate sumoylation at these sites and significantly reduces PR 
transcriptional activity in the presence of hormone (Abdel-Hafiz & Horwitz 2014). PIAS1 was 
shown to sumoylate the MCR in five positions; Lys89, 399, 428, 494 and 953. Of these 
Lys953 was in the LBD and the rest were in the NTD. These sumoylations were shown to 
repress target gene expression dependent on promoter context (Faresse 2014).  
 
  
51 
 
1.10 - Steroid Receptor Roles in Cancer and Disease 
As demonstrated the SRs have an array of functions across several tissue types. As a result, 
alterations in SR signalling has been linked to the development of multiple disease.  
 
1.10.1 - Breast Cancer 
In BCa there is involvement of ERα, AR and PR within its complex carcinogenic profile. The 
ERα is the primary SR linked with BCa and is known to be crucial in the development, 
growth, reproduction and maintenance of the breast organs (Lee et al. 2012). Sustained 
exposure of E2 is thought to be a key stimulatory event in the development BCa, mediated 
via the ERα (Yue et al. 2005). The exact mechanism by which E2 signalling drives 
tumorigenesis is unclear, but there are two main hypotheses’ – (i) E2 stimulates cells within 
the mammary gland which causes proliferation and the subcellular processes which cause 
tumorigenesis. This includes DNA synthesis, where mutational errors can occur and disrupt 
cellular processes. Under sustained E2 the proliferation continues and causes the 
accumulation of mutations which ultimately leads to cancer. (ii) E2 metabolism leads to the 
production of genotoxic by-products that directly mutate DNA and once again accumulate 
under sustained E2. A study concluded that it is likely that both hypotheses occur and act 
synergistically (Yue et al. 2005). In addition to the carcinogenic effects induced by E2, these 
effects are further propagated by PTMs of the ERα. Primarily phosphorylation events within 
the AF1 domain enhance transcriptional activity and expression of tumour promoting genes. 
Two phosphorylation sites, Ser118 and Ser167, are targeted by several different kinases in 
the presence of E2. Ser118 can also be phosphorylated independently of E2 when 
Epidermal Growth Factor (EGF) stimulates the MAPK pathway. For example, CDK7 
phosphorylates this site in response to both stimuli. This results in increased association with 
co-factors such as the p160 family. In clinical terms, this phosphorylation results in more 
differentiated cells with better prognosis and a better response to early tamoxifen treatment 
(Anbalagan & Rowan 2015). However, if the MAPK stimuli continues it can promote 
hormone-independent cancer. In such a situation, phosphorylation of Ser167 increases the 
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binding of the receptor to DNA and Steroid Receptor Co-activator 3 (SRC3), resulting in 
enhanced transcription. For example the gene CUEDC1 is an ERα target gene which is 
essential for BCa proliferation (Lopes et al. 2018).  
 
Treatment of ERα+ BCa is primarily through anti-estrogen therapy such as tamoxifen which 
competes with E2 for the ERα. Additionally aromatase inhibitors are regularly used to 
attenuate conversion of androgens to estrogens thus depleting E2 levels in the patient 
(Droog et al. 2013). The AR is also largely expressed in BCa irrelevant of ERα expression 
status. In AR+/ERα- BCa, the AR gene expression profile resembles that of ERα in ERα+ 
BCa, therefore demonstrating that in some cases, the AR can also drive BCa growth. 
Further, AR overexpression has been shown to contribute to estrogen-based therapy 
resistance in BCa model systems (De Amicis et al. 2010). The role of AR in both ERα+ and 
AR+/ERα- BCa remains unclear. However, some mechanisms of AR gene regulation have 
started to emerge; AR was shown to interact with the MAPK pathway via ErbB2, regulating 
ERK phosphorylation and its downstream effectors the RSKs and in turn EIk-1 and c-Fos in 
ERα-/AR+ BCa (Chia et al. 2015). Anti-androgen therapy would be the logical treatment for 
ERα-/AR+ BCa and enzalutamide, a potent AR antagonist, has been shown to reduce the 
proliferation of both ERα+/AR+ and ERα-/AR+ BCa (Cochrane et al. 2014).  
 
The role of PR is controversial in BCa with some studies showing proliferative effects and 
other repressive. PR was shown to increase the responsiveness of MCF7 cells to E2 by 
transcribing a subset of ERα target genes. Cells stably expressing PR also showed 
enhanced ERα S167 phosphorylation and recruitment of several co-factors to EREs which in 
the case of ERα+ BCa led to increased expression of target genes (Daniel et al. 2015). 
Furthermore, knockdown of endogenous PR in multiple BCa cell lines was shown to reduce 
expression of these target genes, reduced growth in soft agar and partially restored 
tamoxifen sensitivity, therefore highlighting the receptors proliferative attributes (Daniel et al. 
2015). Conversely PR was shown to reduce tumour volume in MCF-7 mouse xenografts in 
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comparison to the ERα+ xenografts which exhibited tumour growth. PR also inhibits growth 
in primary breast tumour explants. CHIP analysis was performed in the presence of E2 and 
progesterone, this reveals 3603 differential ERα binding events than with E2 alone, 
suggesting that PR influences the selectivity of ERα binding (Mohammed et al. 2015). 
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1.10.2 - Prostate Cancer 
The AR is the primary SR concerning PCa. Testosterone enters prostate cells where it is 
metabolised into its more potent form, DHT, which induces the transcription of target genes, 
such as Prostate Specific Antigen (PSA) and transmembrane protease serine 2 (TMPRSS2).  
This regulation of transcription promotes cell growth and survival (Tan et al. 2015). 
Development and progression of PCa is dependent on androgen stimulation. Therefore, the 
primary treatment for PCa is Androgen Deprivation Therapy (ADT) or inhibition of receptor 
function. However, this is a short-term solution, as relapse occurs due to therapy resistance 
and development of castrate resistant prostate cancer (CRPC) (Litwin & Tan 2017).  
 
PCa is initiated by activation growth promoting pathways, for example AR upregulates fusion 
proteins such as E-Twenty-Six Variant 1 (ETSV1) which causes cell cycle progression 
(Rubin et al. 2011). Additionally dysregulation of proliferative pathways such as MAPK and 
PI3K have been shown to contribute to initiation and disease progression (Taylor et al. 
2010). The NTD of the AR contains two types of repeated structure: polyglutamine (CAG) 
and polyglycine (GGG) repeats. It has been shown that men with CAG repeats shorter than 
21/22 are at a higher risk of developing PCa. This is because these repeats affect the 
transcriptional activity of AR, with shorter repeat lengths leading to a more transcriptionally 
active AR (Neto et al. 2008). Several mechanisms have been implicated in CRPC 
development. During ADT therapy, AR levels are significantly reduced, therefore the AR 
gene is often amplified to increase the sensitivity of the cell to the current androgen 
concentrations and allowing for proliferation to again occur. This is present in approximately 
30% of CRPC patients (Yuan et al. 2014). Mutations in the AR have also been linked to 
CRPC and cause the AR to have increased affinity to androgen or to respond to other 
steroid hormones (Taplin et al. 2003). Increased expression of co-factors has been 
demonstrated in the development of CRPC. The dysregulated expression of co-factors 
SRC1 and Transcriptional Intermediate Factor 2 (TIF2) enhance AR transcriptional activity 
and increase proliferation (Gregory et al. 2001). The AR is also activated in a ligand-
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independent manner via PTMs which regulate its transcriptional activity, most commonly by 
phosphorylations (Katzenwadel & Wolf 2015).  
 
New therapies are being developed as a treatment option for CRPC.  For example, drugs 
that target the NTD of the AR have been developed. However the development of such 
drugs has proved more difficult than current drugs that target the LBD as there is less 
intrinsic order in this domain of the protein with few secondary structures (Assi et al. 2016). 
Although not considerable, ERα has been shown to contribute to prostatic growth and 
development.  KO models have shown ERα as an important mediator of prostate 
carcinogenesis and treatment with anti-estrogens significantly decreased early PCa 
progression (Jia et al. 2015).  
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1.10.3 - Ovarian Cancer 
As with BCa and PCa, ERα target genes can result in the upregulation of proliferative genes 
which promotes the development of, and drives the progression of, ovarian cancer. The 
treatment for OvCa is limited due to a poor response to the widely used ERα antagonist 
tamoxifen with approximately 10-15% of patients responding. This means often 
cytoreductive surgery is necessary (De Stefano et al. 2011). OvCa mainly regards the 
primary ER isoform ERα. The isoform ERβ plays a significant tumour suppressive role in the 
ovaries and is the primarily expressed isoform but is seen to be significantly downregulated 
in this disease. In addition, the proliferative isoform ERα shows the inverse relationship, 
weaker expression in normal tissues but upregulated in cancer. These changes in ERa 
expression appear to be regulated by the tumour suppressor microRNA 206 (miR206), 
which is downregulated in ovarian cancer.  Interestingly, reintroduction of this miR in the 
ovarian cancer cell lines CAOV-3 and BG-1 inhibits proliferation (Li et al. 2014). 
Conversely, agonistic activation of ERβ was shown to reduce proliferation in the OV2008 cell 
line which has an unbalanced ratio of ERα:ERβ 14:1, highlighting the strong suppressive 
effects of ERβ (Chan et al. 2014).  
 
1.10.4 - Glucocorticoid Resistance 
As mentioned previously, the GR is pivotal in the regulation of the immune system, as such 
GCs are regularly used to alleviate inflammation. However, long term use of GC can lead to 
GC resistance (GCR), resulting in a return of the disease symptoms such as asthma, 
rheumatoid arthritis (RA) and Chronic Obstructive Pulmonary Disease (COPD) (Vandewalle 
et al. 2018). The underlying mechanism which causes GCR is caused by the inflammatory 
responses, mostly cytokines, that the GCs themselves are trying to inhibit. Inhibition of these 
molecules has been shown to reverse GCR, for example inhibition of TNFα restores GC 
sensitivity in asthma mouse models (Dejager et al. 2015) and inhibition of the IL-2 returned 
sensitivity to inflammatory bowel disease patients (Creed et al. 2006). In a converse manner 
activation of proteins negatively regulated by GCR can alleviate the symptoms. Inflammatory 
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stimuli have been shown to reduce activity of HDAC2, reactivation via theophylline restored 
GC sensitivity (Ford et al. 2010). Additionally, stress has also been implicated in GCR, the 
study concluded that long term stressors can cause the development of GCR and interferes 
with inflammation (Cohen et al. 2012).  
 
1.10.5 - Heart Disease 
Myocardial Infarction (MI) rodent models were used to investigate the relationship between 
the MCR and heart disease. Inactivation of MCR was shown to attenuate left ventricle 
dilation, cardiac hypertrophy and the development of Heart Failure (HF). Whereas MCR 
overexpression causes these phenotypes. Expression of MCR is upregulated in the MI 
mouse models in response to a high-salt diet (de Resende et al. 2006). Additionally the 
presence of aldosterone and salt induces an inflammatory response causing the 
upregulation of cytokines such as TNFα (Martín-Fernández et al. 2014). These effects can 
be counteracted with MCR directed therapy, which reached clinical trials. Across three 
randomised clinical trials, treatment with a MCR antagonist in patients with HF showed 
significantly reduced mortality and morbidity across all causes of death in comparison to the 
control (Bauersachs et al. 2015).  
 
1.11 - Summary 
To conclude, RSKs are the most downstream kinases of the MAPK pathway and the SRs 
are nuclear transcription factors which mediate essential and diverse functions throughout 
the body. Both families of proteins have been shown to interact and have been implicated in 
several diseases, including cancer. However, little is known about the cross-talk between 
these families. As such I aim to complete a comprehensive study of the interactions between 
the RSKs and SRs. I plan to do this by using recombinant DNA techniques to clone all 
proteins into mammalian expression vectors. The proteins will then be co-overexpressed, 
and luciferase reporter assays performed to quantify changes in SR activity in response to 
RSK signalling. 
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1.12 – Hypothesis, Aims and objectives 
 
The hypothesis of this project is that different RSK isoforms regulate different SRs, which 
contributes to development and progression of hormone driven cancers. As such the aims of 
this project are to: i) Determine which RSKs regulate which SRs, ii) Determine if PMA 
enhances RSK activation of the SRs, iii) Determine if RSK phosphorylation state effects 
regulation of SR activity. This will be achieved by the following objectives: i) Cloning all 
RSKs into PCDNA3.1 (+) for luciferase assays. ii) Use site directed mutagenesis to create 
RSK mutants, iii) Use Luciferase assays to achieve each aim.   
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Chapter 2 - Methods and Materials 
 
2.1 - Molecular Cloning  
 
 
2.1.1 - PCR Primer design 
The RSK and MCR DNA sequences were obtained from Uniprot (Consortium, 2017) a 
protein database. From these sequences primers were designed for DNA amplification via 
PCR. Primers physical properties were estimated using an online TM and GC calculator (Tm 
Calculator). The primer pairs were designed to have similar Tm values to increase annealing 
efficiency. GC content was relatively high at 46% and above to increase binding efficiency of 
primers to DNA template. Similar sequences were avoided to prevent primer dimer formation 
(Table 2.1.1.1) 
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Table 2.1.1.1 Properties of Primers used for PCR of RSK1-4, PCR of MCR and HA 
annealing  
Tm and GC% were calculated with an online bioinformatic tool (Tm Calculator). Forward 
primers are indicated by (Fwd) and reverse primers are indicated by (Rev). 
Primer Sequence Length  Tm GC% 
HA tag 
NheI 
(Fwd)  
 
5’-CTAGCGATGTACCCATACGATGTTCCAGATTACGCTA-3’ 
 
37  
 
66 
 
46 
HA tag 
HindIII 
(Rev)  
 
5’-AGCTTAGCGTAATCTGGAACATCGTATGGGTACATCG-3’ 
 
37 
 
66 
 
46 
RSK1 
NOTI 
(Rev) 
 
5’-GGAATTCGCGGCCGCTCACAGGGTGGTGGATGG-3’ 
 
33 
 
72 
 
67 
RSK1 
KPNI  
(Fwd) 
 
5’-GCAATTCGGTACCATGCCGCTCGCCCAGCT-3’ 
 
30 
 
68 
 
63 
RSK2 
NOTI 
(Rev) 
 
5’-GGAATTCGCGGCCGCTTACAGGGCTGTTGAGGTGA-3’ 
 
35 
 
70 
 
60 
RSK2 
KPNI 
(Fwd) 
 
5’-GCAATTCGGTACCATGCCGCTGGCGCAGCTGGC-3’ 
 
33 
 
72 
 
67 
RSK3 
NOTI 
(Rev) 
 
5’-GGAATTCGCGGCCGCTCACAGCCGCGT-3’ 
 
27 
 
69 
 
70 
RSK3 
KPNI 
(Fwd) 
 
5’-GCAATTCGGTACCATGGACCTGAGCATGAAGAA-3’ 
 
33 
 
64 
 
48 
RSK4 
NOTI 
(Rev) 
 
5’-GGAATTCGCGGCCGCTTACAGGCCAGTTGATGTTCG-3’ 
 
36 
 
70 
 
58 
RSK4 
KNPI 
(Fwd) 
 
5’-GCAATTCGGTACCATGCTACCATTCGCTCCTCAG-3’ 
 
34 
 
67 
 
53 
MCR 
XmaI 
(Fwd)  
 
5’-CCCGGGATGGAGACCAAA-3’ 
 
18 
 
53 
 
61 
MCR  
BglII 
(Rev)  
 
5’-AGATCTTCACTTCCGGTGGAAGTAGA-3’ 
 
26 
 
58 
 
46 
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2.1.2 - Transformation of E.coli DH5α for DNA plasmid amplification 
1 µl of plasmid DNA or 5 µl of Ligation mixture was added to 50 µl of DH5α E. coli competent 
cells (Thermo scientific) and incubated on ice for 30 minutes. The cells were then heat-
shocked in a water bath at 42oC for 45 seconds. The cells were then incubated on ice for 2-5 
minutes. 500 µl of Luria Broth (LB) (or 200 µl for ligation) were then added to the cells, 
followed by an hour incubation at 37oC with shaking. Cells were then diluted in 10ml of LB 
or, for ligation, spread on LB agar plates; 100µg/ml Ampicillin of LB for both PCDNA 3.1 (+) 
and PSG5 vectors. The cultures/plates were incubated overnight at 37oC. Any steps that 
include exposing the cells to naked air were done in a class II microbiological safety cabinet 
to reduce the likelihood of contamination. 
 
2.1.3 - Plasmid Miniprep  
Minipreps were completed using the Thermo Scientific GeneJet Plasmid miniprep kit. 
Cell cultures were centrifuged for 10 minutes at 4000G in a Thermo Scientific Heraeus 
Megafuge 40R bench top centrifuge. The supernatant was discarded and the pellet was re-
suspended in 250 µl of resuspension buffer, lysed with 250 µl of Lysis buffer and 350 µl of 
neutralisation buffer added. The mixture was centrifuged at 11,400G for 10 minutes in a 
Thermo Scientific minispin microcentrifuge. The supernatant was then transferred to a 
miniprep column and centrifuged for one minute at 11,400g. 500 µl of wash buffer was 
added to the column and centrifuged for one minute at 11,400g. The wash was repeated 
once more. The column was then centrifuged for 90 seconds at 11,400g to remove the 
residual wash buffer and transferred to an Eppendorf microcentrifuge tube. 40 µl of water 
was added and the column left to stand at RT for 1-2 minutes before centrifugation at 
11,400G for one minute to elute the DNA. 
 
2.1.4 - PCR DNA amplification 
PCR was used to amplify RSK1-4 DNA and MCR DNA (Table 1.1.1). (Table 2.1.4.1) shows 
the volumes of each component of a PCR reaction, (Table 2.1.4.2) shows the conditions 
used and (Table 2.1.4.3) shows the variable annealing temperature for the RSKs and MCR.  
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Table 2.1.4.1 PCR reaction mixture, volumes and concentrations of reagents 
Volume Component 
10 µl 5X Phusion DNA Polymerase GC buffer 
(Thermo Scientific) 
5 µl Dimethyl sulfoxide (DMSO) 100% 
1 µl dNTPs mix (Thermo Scientific, 200mM)   
1 µl Primer mix (250ng/µl) 
1 µl DNA template (100-250ng/µl) 
1 µl Phusion DNA Polymerase (Thermo 
Scientific, 2U/µl) 
31 µl H2O 
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Table 2.1.4.2 PCR program used. X depicts variable annealing temperatures 
dependent on gene of interest. 
Temperature (oC) Time (minutes) Process Number of cycles  
98 10 Initial denaturation  1 
98 1 Denaturation  
30 X 1 Annealing 
72 1 Extension  
72 10 Final extension  1 
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Table 2.1.4.3 Annealing temperatures of RSKs and MCR.  
Annealing Temperature (oC) Gene of interest 
60 RSK1-4 
54 MCR 
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2.1.5 HA annealing  
The HA forward and reverse primers were annealed in a buffer containing 10mM Tris (pH 
7.5), 50mM NaCl and 10mM to create the HA tag. Reaction mixture and annealing program 
are shown by (Table 2.1.5.1 and 2.1.5.2) respectively.  
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Table 2.1.5.1 HA annealing reaction mixture, volumes and concentrations of reagents 
Volume Component 
2.5 µl Primer 1 (100µM) 
2.5 µl Primer 2 (100µM) 
45 µl Buffer 
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Table 2.1.5.2 HA annealing program used  
Temperature (oC) Time (minutes) Process 
98 2 Initial denaturation  
25 45 Annealing  
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2.1.6 - Agarose Gel Electrophoresis  
RSK and MCR PCR products were purified on 2% and 1.5% w/v agarose gels respectively. 
Double digested RSK and MCR DNA, PCDNA 3.1(+) and PSG5 plasmids were purified on a 
1% w/v agarose gel. Ligation double diagnostic digests were run on 1% w/v agarose gels. 1 
µl of Gel Red Nucleic acid stain (50,000X) was added per 50ml of agarose. Thermo 
Scientific 1Kb Gene ruler and 100bp DNA ladders (0.5µg/ µl) were also used in lanes to 
check the size of DNA. Electrophoresis was carried out at 100V from 40-60 minutes. DNA 
bands were visualised using a Syngene UV illuminator.  
 
2.1.7 - Gel Extraction   
DNA was extracted from agarose gels and purified using the GeneJET Gel Extraction Kit 
(Thermo Scientific). All centrifugation steps were carried out on a Thermo Scientific minispin 
microcentrifuge at 11,400 G. DNA was solubilised by adding one volume of solubilisation 
buffer to one volume of gel (i.e. 100 µl of buffer per 100mg of gel) and heated at 55oC for 10 
minutes, vortexing the sample every two minutes. The solution was then transferred to a gel 
extraction column, centrifuged for one minute and the flow through discarded.  An additional 
100 µl of binding buffer were added to the column and centrifuged for one minute. 700 µl of 
wash buffer were added and then centrifuged for one minute. The microcentrifuge tube was 
centrifuged for 90 seconds, to remove the residual wash buffer, and the column transferred 
to an Eppendorf microcentrifuge tube. 40 µl of water was added to the column, left to 
incubate at RT for 1-2 minutes before centrifugation for one minute to elute the DNA.  
 
2.1.8 - Double digests of RSKs, PCDNA 3.1 (+), MCR, PSG5 and HA tag 
To generate sticky ends, RSKs and PCDNA 3.1 (+) vector were digested with KpnI and NotI. 
MCR and PSG5 vector were digested with XmaI and BgIII. The HA tag was digested by XhoI 
at two positions. Reaction mixtures (Table 2.1.8.1) were incubated at 37oC.  
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Table 2.1.8.1 Restriction enzyme double digest, volumes and concentrations of 
reagents     
Volume Component 
5 µl 10X FD buffer green (Thermo Scientific) 
1 µl  1st RE (Thermo Scientific, 10U/µl) 
1 µl 2nd RE (Thermo Scientific, 10U/µl) 
35 µl / 20 µl Insert DNA/ Vector DNA (30-100ng/µl) 
Make up to 50 µl  H2O 
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2.1.9 - Ligation of RSKS into PCNDA 3.1(+) vector, MCR into PSG5 vector and HA tag into 
PCDNA 3.1(+) 
Digested vectors and inserts were ligated together using T4 DNA ligase. To increase 
success of ligation, excess insert concentration to plasmid was used (Table 2.1.9.1). The 
plasmids were transformed into competent bacteria (section 2.1.2).  The resulting colonies 
were grown in 10ml LB culture with 100µg/ml Ampicillin and left to grow overnight. Ligation 
product was then purified using Plasmid Miniprep (section 2.1.3). 
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Table 2.1.9.1 Ligation mixture volumes and concentrations of reagents 
Volume Component  
 
3 µl 10X T4 ligase buffer (Thermo Scientific) 
1 µl Vector DNA (100-300ng/µl) 
25 µl Insert DNA (50-100ng/µl) 
1 µl T4 DNA ligase (Thermo Scientific) 
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2.1.10 - Diagnostic digest check 
Recombinant DNA was double digested to confirm successful ligation. (Table 2.1.10.1) 
shows the components of a double digest check. Samples were incubated for 3 hours at 3oC 
and then run on a 1% agarose gel at 100V for 45 minutes.  
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Table 2.1.10.1 Diagnostic digest check volumes and concentrations of reagents 
  
  
Volume Component   
1 µl Plasmid (1-2µg) 
1 µl 1st Restriction Enzyme (Thermo Scientific, 
10U/µl) 
1 µl 2nd Restriction Enzyme (Thermo Scientific, 
10U/µl) 
1 µl buffer 
6 µl H2O 
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2.1.11 - Site directed mutagenesis  
Primers were designed to incorporate a single amino acid mutation on the N-terminal 
phosphorylation site of each RSK isoform. The primers were designed using an online tool 
by Agilent (Agilent 2002), primer length and Tm were kept constant so that all newly 
synthesised DNA is identical (Table 2.1.11.1-4). The primers were then mixed with additional 
components (Table 2.1.11.5) to create a mutagenesis reaction mixture which was then put 
through a designated mutagenesis program to the mutants (Table 2.1.11.6). 
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Table 2.1.11.1 Primers properties used for Site directed mutagenesis of RSK1 
Primers for RSK1 S221E Length
(bp)  
Tm Duplex 
energy at 
68oC  
Energy 
cost of 
mismatche
s  
5'-
ccacgagaagaaggcctatgaattctgcgggacagtgga
g-3' 
 
40 
 
78.65
℃ 
 
-58.33 
kcal/mol 
 
0.77% 
5'-ctccactgtcccgcagaattcataggccttcttctcgtgg-
3' 
40 78.65
℃ 
-56.50 
kcal/mol 
1.74% 
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Table 2.1.11.2 Primers properties used for Site directed mutagenesis of RSK2 
Primers for RSK2 S227E 
 
Length 
(bp) 
Tm Duplex 
energy 
at 68oC 
Energy cost 
of 
mismatches  
5'-tctattgaccatgaaaagaaggcatat 
gaattttgtggaactgtggagtatatggc-3' 
 
56 78.73℃ -58.60 
kcal/mol 
.77% 
5'-gccatatactccacagttccacaaaatt 
catatgccttcttttcatggtcaataga-3' 
56 78.73℃ -60.05 
kcal/mol 
1.64% 
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Table 2.1.11.3 Primers properties used for Site directed mutagenesis of RSK3 
Primers for RSK3 S218E 
 
Length 
(bp) 
Tm Duplex 
energy at 
68oC 
Energy cost 
of 
mismatche
s  
5'-ctcgatcgtcccgcagaattcgtacgctctcttgtcgtg-
3' 
39 78.58
℃ 
-53.16 
kcal/mol 
10.28% 
5'-
cacgacaagagagcgtacgaattctgcgggacgatcga
g-3' 
39 78.58
℃ 
-55.70 
kcal/mol 
9.55% 
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Table 2.1.11.4 Primers properties used for Site directed mutagenesis of RSK4 
Primers of RSK4 S232E 
 
Length 
(bp)  
Tm Duplex 
energy 
at 68oC 
Energy 
cost of 
mismatch
es  
5'-
catatactctactgtaccacaaaattcgtaagccttcttttcttgat
ctac-3' 
51 78.01
℃ 
-46.73 
kcal/mol 
6.35% 
5'-
gtagatcaagaaaagaaggcttacgaattttgtggtacagtag
agtatatg-3' 
51 78.01
℃ 
-50.06 
kcal/mol 
2.76% 
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Table 2.1.11.5 Mutagenesis reaction volumes, concentrations and mass of reagents 
Volume/mass Component 
10 µl 5X Phusion DNA Polymerase GC buffer 
(Thermo Scientific) 
1 µl 200mM dNTPs mix (Thermo Scientific)   
1 µl 250ng/µl Primer mix  
50ng DNA template 
1 µl Phusion DNA Polymerase (Thermo 
Scientific) 
Make to 50 µl H2O 
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Table 2.1.11.6 Mutagenesis program used  
Temperature (oC) Time (minutes) Process Number of 
cycles 
98 3 Initial denaturation  1 
98 1 Denaturation  
18 55 1 Annealing 
68 3 Extension  
68 10 Final extension  1 
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2.1.12 - Sequence analysis  
Purified plasmids were sequenced by Eurofins to check if the insert had successfully been 
ligated into the vector with no point mutations or to check if site directed mutagenesis was 
successful and contained no additional undesired mutations. DNA sequences were 
translated into amino acids using the online Expasy Translate tool (Gasteiger et al. 2003). 
The Clustal Omega Multiple sequence alignment tool (Goujon et al. 2010) was then used to 
align the sequencing results with sequences obtained from uniprot database (Consortium 
2017). 
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2.1.13 - DNA midi prep 
RBC Bioscience Fast Ion Plasmid Midi Advanced Kit was used to generated high-purity 
plasmids for mammalian cell transfection. DH5α cells were transformed and grown ON in 10 
ml LB. This pre-culture was then diluted in 200ml of LB containing 100µg/ml of ampicillin and 
incubated at 37oC until the OD600 reached a value between 2-4 The cells were then aliquoted 
into four sterile 50ml falcon tubes and centrifuged at 6000G for 15 minutes at 4oC. The 
supernatant was discarded and the cells resuspended in 10ml of PM1 buffer. The 
resuspended cells were transferred to a 30ml centrifuge tube and 10ml of PM2 buffer added.  
The mixture was inverted 10-15 times before being left to stand at RT for five minutes. In the 
meantime, a PMI column was equilibrated with 10ml of PEQ buffer. Once the lysate had 
cleared 10ml of PM3 buffer was added to the solution, inverted 10-15 times and left to stand 
at RT for five minutes. The solution was then centrifuged at 15,000G for 15 minutes at 4oC. 
The supernatant was transferred to the column and then washed with 15ml of PWA buffer. 
10ml of PEL buffer was added to the column and the eluted DNA was collected in a new 
sterile 30ml centrifuge tube. 7.5ml of isopropanol was added, the tube inverted 10-15 times 
and then left to stand at RT for 2-5 minutes. The mixture was centrifuged at 20,000G for 30 
minutes at 4oC. The liquid was carefully removed prior to the addition of 5ml of 70% ethanol 
and the tube centrifuged at 20,000G for 10 minutes at 4oC. The supernatant was again 
discarded. The DNA pellet was left to stand at room temperature until dry. Dependent on 
pellet size an appropriate volume of sterile water was used to dissolve the DNA and this was 
transferred to a sterile 1.5ml Eppendorf.  
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2.2 - Cell Culture 
Monkey COS-1 cells were maintained in DMEM or stripped DMEM media, supplemented 
with 5% Foetal Bovine Serum (FBS) or 2% double charcoal stripped FBS respectively. Both 
variations of DMEM were also supplemented with Penicillin (100 U) - Streptomycin (0.1 
mg/mL) - L-Glutamine (2 mM) (PSG). All manipulations were performed under sterile 
conditions inside a Class II microbiological cabinet and cells were incubated in humidified air 
containing 5% CO2 at 37oC.  
 
2.2.1 - Passaging cells 
Cells were passaged every time they reached 70-80% confluency. Old media was removed, 
the cells were then washed with Phosphate Buffered Saline (PBS) and, dependent on flask 
size, 0.75-1.5ml of Trypsin/EDTA was added.  The cells were incubated for a few minutes at 
37oC to detach the cells from the flask surface. The trypsinised cells were then resuspended 
in 10ml of media and the desired volume of cells were added to a new flask containing 
preheated media and placed back into the incubator. 
 
2.2.2 - Plating cells 
Cells were passaged every time they reached 70-80% confluency. Old media was removed, 
the cells were then washed with Phosphate Buffered Saline (PBS) and, dependent on flask 
size, 0.75-1.5ml of Trypsin/EDTA was added.  The cells were incubated for a few minutes at 
37oC to detach the cells from the flask surface. The trypsinised cells were then resuspended 
in 10ml of media and the desired volume of cells were added to a new flask containing 
preheated media and placed back into the incubator. 
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2.2.3 - Calcium Phosphate Transfections 
100 µl of transfection mixture was pipetted dropwise into each well of a 24 well plate and 
incubated for 20-24 hours. The transfection mixtures varied dependent on experimental 
design. All transfection mixtures contained a set combination of DNA plasmids at set 
concentrations in addition to CaCl2 and Borate Buffered Saline (BBS). The DNA plasmids 
were added first, 2M CaCl2 was then added in a swirling manner followed by bubbling to mix 
the solution, BBS was added last in the same manner. The mixtures were left to incubate at 
RT for 15 minutes before being transferred onto cells. (Table 2.2.3.1-5) highlight the 
components of all transfection mixes for different experiment sets. 
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Table 2.2.3.1 Hormone optimisation experiments - volumes and concentrations of 
reagents added per well 
Volume per well Component 
0.5 µl Steroid receptor plasmid (100ng/µl) 
2 µl Luciferase plasmid (500ng/µl) 
1 µl Β-gal plasmid (10ng/µl) 
41.5 µl H2O  
5 µl 2M CaCl2 
50 µl BBS 
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Table 2.2.3.2 DNA optimisation experiments – volumes and concentrations of 
reagents added per well 
Volume  Component 
0.5 µl Steroid receptor plasmid (100ng/µl) 
2 µl RSK plasmid (0/100/200ng/µl) 
2 µl Luciferase plasmid (500ng/µl) 
1 µl Β-gal plasmid (10ng/µl) 
39.5 µl H2O 
5 µl 2M CaCl2 
50 µl BBS 
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Table 2.2.3.3 Volumes of plasmid used to create the different DNA concentrations. 
 RSK condition  
0ng 100ng 200ng 
Empty vector 
(100ng/µl) 
9 µl 4.5 µl 0 µl 
RSK DNA (100ng/µl) 0 µl 4.5 µl 9 µl 
Total Volume 9 µl 9 µl 9 µl 
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Table 2.2.3.4 PMA induction experiments – volumes and concentrations of reagents 
added per well  
Volume  Component 
0.5 µl Steroid receptor plasmid (100ng/µl) 
1 µl RSK plasmid (100ng/µl) 
2 µl Luciferase plasmid (500ng/µl) 
1 µl Β-gal plasmid (10ng/µl) 
40.5 µl H2O 
5 µl 2M CaCl2 
50 µl BBS 
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Table 2.2.3.5 Phospho-mimetic experiments – volumes and concentrations of 
reagents added per well  
Volume  Component 
0.5 µl Steroid receptor plasmid (100ng/µl) 
1 µl RSK plasmid (100ng 
2 µl Luciferase plasmid (500ng/µl) 
1 µl Β-gal plasmid (10ng/µl) 
40.5 µl H2O 
5 µl 2M CaCl2 
50 µl BBS 
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2.2.4 - Hormone/drug treatments 
COS-1 cells were treated with preheated hormone-depleted DMEM media and 
hormones/drugs 20-24 hours after they were transfected. Stock hormone concentrations 
were prepared 1000x more concentrated than the desired final concentration to allow a 
dilution factor of 1:1000. Prior to treatment, cells were washed two times with 0.5ml of 
preheated hormone-depleted DMEM media. The hormone optimisation experiments used 
varied concentrations (0, 0.1, 1, 10, 100, 1000nM) of the corresponding hormone to steroid 
receptor. The DNA optimisation experiments used a set concentration of hormone 1nM, 
10nM, 10nM, 1nM with regards to AR, GR, ER, PR respectively. In addition to this there was 
a 100% ethanol control for each condition which was also diluted in preheated hormone-
depleted DMEM at the same ratio as hormone. The DNA optimisation experiment conditions 
were used for the PMA induction experiments except 200nM of PMA was also added to 
corresponding wells. The DNA optimisation experiment conditions were used for the 
phosphor-mimetic experiments.  
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2.2.5 - Cell lysis, β-galactosidase and Luciferase assays 
All media was removed from the 24 well plate and cells were washed 2 times with 0.5ml of 
PBS. 60 µl of Promega Cell Culture Lysis Reagent was added to each well and the plate 
was frozen for 15 minutes at -80oC. The plates were left to thaw and kept on ice for the 
duration of the assay. For the luciferase assays, 20 µl of cell lysate was taken from each well 
and added to individual wells of a 96 well plate. 20 µl of Promega Luciferase Substrate was 
added to each well and the plate was covered with foil and rotationally mixed for 15 minutes 
at room temperature. The plate was again read on a FLUOstar Omega Plate Reader. 
For the β-galactosidase assay, 5 µl of cell lysate was taken from each well and added to 
individual wells of a 96 well plate. 50 µl of Tropix Galacton-Plus was then added to each 
well, the plate was covered with foil and rotationally mixed for one hour at room temperature. 
75 µl of Tropix Accelerator II was added to each well, the plate was re-covered with foil and 
mixed rotationally for 15 minutes at room temperature. The plates were then read 
immediately on a FLUOstar Omega Plate Reader.  Luciferase data were normalised using 
the β-galactosidase results. 
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2.3 - SDS-PAGE 
Protein concentration was measured on a Nanodrop ND-1000 Spectrophotometer on the 
protein A280 setting. In addition to these readings known concentrations of BSA were 
measured and a standard curve generated. 4.17 µl of Lamelli loading dye was added to 
40µg of each sample and lysis buffer was added to make all samples to the same final 
volume. Samples were boiled for ten minutes at 90oC and immediately placed on ice. The 
samples were loaded onto a 12% SDS-PAGE (Table 2.3.1). 4 µl of Thermofisher Prestained 
Protein PageRuler Ladder was added to one well and 4 µl of laemmeli loading dye was 
added to any empty wells. The gel was then run in running buffer (Table 2.3.1) at 180V until 
the dye front ran off the gel.  
 
Once the SDS-PAGE was completed the proteins present were transferred onto a PVDF 
membrane. Five pieces of electrode paper were soaked in transfer buffer (Table 2.3) and 
placed on the BIO-RAD trans-blot semi-dry transfer cell. A piece of membrane was cut to 
similar size as the electrode paper and soaked in methanol. The membrane was then 
soaked in transfer buffer and placed on top of the PDVF membrane. The SDS-PAGE was 
then placed on top of the membrane. The last 5 pieces of PDVF paper were then soaked in 
transfer buffer, placed on top of the SDS-PAGE and rolled to remove any potential bubbles. 
The electrode plates were then dampened with transfer buffer to ensure current flow. The 
SDS-PAGE was then transferred for two hours at 15V and 100mA. 
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Table 2.3.1 Reagents used for SDS-PAGE  
Reagent Components 
SDS-PAGE (12%) Per gel, a 12 % resolving gel was made;  
4mL Acrylamide/Bis-acrylamide 30 % 
solution (Sigma-Aldrich), 2.6 mL of 1.5 M 
Tris/HCl at pH 8.8, 3.2 mL of ddH2O and 50 
µL of 10 % SDS. Immediately prior to 
pouring, 10 µL of 10 % APS stock and 2.5 
µL N,N,N’,N’Tetramethylethylenediamine 
(TEMED, Sigma-Aldrich) were added.  
Additionally a stacking gel was made; 670 
µL of Acrylamide/Bis-acrylamide 30 % 
solution (Sigma-Aldrich), 1.25mL of 0.5 M 
Tris/HCl at pH 6.8, 3 mL of ddH2O and 50 
µL of 10 % SDS. Immediately prior to 
pouring, 10 µL of 10 % APS and 5 µL 
TEMED were added.  
Running buffer 3 g of Tris base (25 mM, Fisher Scientific), 
14.45 g of Glycine (0.2 M, Fisher Scientific) 
and 0.5 g of SDS (0.05 %, Fisher Scientific) 
were dissolved in a total volume of 1 L 
ddH2O. 
Transfer buffer 5.63 g Glycine (150 mM, Fisher Scientific), 
1.22 g Tris base (20 mM) and 100 ml of 
Methanol (20 %, MeOH, Fisher Scientific), 
dissolved in a total volume of 500 mL 
ddH2O. 
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2.4 - Immunoblotting 
1g of powdered milk was dissolved in 20ml of PBS-0.1% tween (PBST) creating a 5% 
PBST-milk solution. The 5% PBST-milk was added to the PVDF membrane and incubated at 
room temperature for 30 minutes. The block was removed and primary antibodies were 
added.  The primary antibodies (Table 2.4.1) were prepared in 5% PBST-milk and incubated 
over night at 4oC with rotation.  The following day the primary antibody was removed and the 
membrane washed three with 5ml of PBST (5min with agitation).  Membranes were blocked 
with 5% PBST-milk for 15 minutes on a roller at room temperature. Secondary antibodies 
(1:2000) were then added and the membrane left for one hour on a rolling machine at RT. 
The wash steps were repeated and a final wash with PBS for five minutes was performed on 
a roller at RT.  After the final PBS wash, 350 µl of Luminata Forte Western HRP substrate 
was continuously pipetted over the membrane for 3 minutes.  The membrane was placed in 
a plastic film and bands visualied using a Fusion FX Vilber Lourmat. 
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Table 2.4.1 Antibodies used for western blots, their targets and the dilutions used. 
Target  Primary Antibody code Dilution used Secondary 
antibody 
(1:2000) 
AR Ab74272 1:1000 Anti-Rabbit 
ERa IR084 1:1000 Anti-Rabbit  
GR Sc-393232 1:500 Anti-Rabbit 
MCR Sc-53000  1:1000 Anti-Rabbit 
PR Sc-166169 1:1000 Anti-Mouse 
RSK1-4 Ab71113 1:100 Anti-Rabbit 
Actin Ab8227 1:1000 Anti-Rabbit 
 
  
96 
 
Chapter 3. Results 
 
3.1 Cloning of the RSKs and Steroid Receptors 
 
It has been demonstrated that some RSKs can regulate the transcriptional activity of certain 
SRs, however not all are characterised. To overcome this a comprehensive study is needed 
to fill the knowledge gap, therefore some of the RSKs and the MCR need to be cloned into 
the appropriate mammalian expression vectors.  
 
The RSKs and MCR were amplified by PCR and isolated via agarose gel electrophoresis.  
The RSKs were amplified and visible at approximately 2000bp which is the correct size. 
Additionally, MCR was amplified and a single band is visible at approximately 3000bp which 
is the correct size (Figure 3.1.1). The genes were then digested with the relevant restriction 
enzymes to create sticky ends for ligation, ligated into the relevant vector and sequence 
verified. Prior to incorporation of the RSK genes into PCDNA 3.1(+), a HA tag was first 
incorporated into the vector to facilitate simple western blotting in later experiments. Both the 
HA tag and PCDNA 3.1(+) were digested with Restriction Enzymes (REs) NheI and HindIII, 
ligated together and sequence verified via sanger sequencing. HA tag containing PCDNA 
3.1 (+) and the RSKs were then digested by NOTI and KPNI, ligated together and sequence 
verified. This positioned the RSK gene directly after the HA tag within the plasmid (Figure 
3.1.2). Through use of several primers the complete gene was sequenced with no mutations, 
including the HA tag at the start of the gene. RSK1 and RSK4 genes were synthesised and 
sequence verified by an external company TWIST, therefore there are no sequence 
alignments. The MCR and PSG5 were digested with XmaI and BgIII, however MCR was not 
successfully ligated into PSG5 vector.  
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Figure 3.1.1 Agarose gel electrophoresis of RSK1-4 and MCR fragmentssite  
RSK1-4 and MCR were amplified by PCR. Loading dye was added to PCR product of RSK1-
4 and MCR and loaded into wells of a 2% agarose gel. The gel underwent electrophoresis at 
100V for 60 minutes, viewed under a Syngene illuminator and images were taken on a 
mobile phone camera.  
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Figure 3.1.2 Multiple sequence alignment of RSK2.  
DNA samples were sent to Eurofins for sanger sequencing. Upon return sequences were 
manipulated to produce one file which shows the composition of DNA sequence. RSK_SEQ 
is the RSK DNA sequence obtained from uniprot, RSK_CMVF is a company primer used to 
sequence the beginning of the gene, RSK_PRIMER is a manually created and synthesised 
primer used to sequence the middle of the gene and RSK_bGHR is a company primer used 
to sequence the end of the gene. Combined use of these primers led to a complete 
sequence for both RSK2 with no mutations.  
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Figure 3.1.3 Multiple sequence alignment of RSK3.  
DNA samples were sent to Eurofins for sanger sequencing. Upon return sequences were 
manipulated to produce one file which shows the composition of DNA sequence. RSK_SEQ 
is the RSK DNA sequence obtained from uniprot, RSK_CMVF is a company primer used to 
sequence the beginning of the gene, RSK_PRIMER is a manually created and synthesised 
primer used to sequence the middle of the gene and RSK_bGHR is a company primer used 
to sequence the end of the gene. Combined use of these primers led to a complete 
sequence for both RSK3 with no mutations. 
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3.2 Site directed mutagenesis of the RSKs to introduce a phospho-mimetic mutation 
The RSKs are the downstream effectors of the MAPK pathway, which is physiologically 
activated by growth factors. However, this may not be sufficient to fully activate the 
overexpressed RSKs. As such, site directed mutagenesis was used to create a phospho-
mimetic mutation in the RSKs activation loop of the N-terminal domain. The purpose of these 
mutations was to create constitutively active RSK mutants for use in luciferase reporter 
assays. Comparisons between wildtype and the phospho-mimetic has been used to infer if 
the endogenous MAPK pathway of the COS-1 cell were activating all the overexpressed 
RSKs. The position of the N-terminal phosphorylation changes between the isoforms due to 
varied isoform sequence and length (Figure 1.1.1). In all isoforms the wildtype Serine (S) in 
the position of the NTKD phosphorylation was mutated into a Glutamic acid (E) all of which 
used the same DNA triplet codon GAA. Glutamic acid was chosen for the mutation as it 
structurally mimics that of a phosphate group. To achieve this, pairs of primers were created 
for each isoform using Agilent site directed mutagenesis primer tool.  
The mutagenesis reactions were transformed into bacteria and single colonies were picked, 
transformed, purified and sequence verified. The sequence was analysed to check if the 
mutation was present and if there were any additional undesired mutations. There is a single 
amino acid mutation of S to E in RSK2, RSK3 and RSK4 at their respective positions 227, 
218 and 232 (Figure 3.2.1). Unfortunately, RSK1 was never successfully mutated without 
additional undesired mutations.  
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Figure 3.2.1 Multiple sequence alignments of RSK2 mutant 2M.   
Site directed mutagenesis was performed on RSK2 in a thermocycler. The mutated DNA 
was amplified, purified and sent to Eurofins for sanger sequencing. Upon return sequences 
were analysed and manipulated. RSK_SEQ is the RSK DNA sequence obtained from 
uniprot, RSK_CMVF is a company primer used to sequence the beginning of the gene, 
RSK_PRIMER is a manually created and synthesised primer used to sequence the middle of 
the gene and RSK_bGHR is a company primer used to sequence the end of the gene. 
Combined use of these primers led to a complete sequence for 2M with the desired 
mutations and no additional mutations. Red box highlights the mutation.  
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Figure 3.2.2 Multiple sequence alignments of RSK3 mutant 3M.   
Site directed mutagenesis was performed on RSK3 in a thermocycler. The mutated DNA 
was amplified, purified and sent to Eurofins for sanger sequencing. Upon return sequences 
were analysed and manipulated. RSK_SEQ is the RSK DNA sequence obtained from 
uniprot, RSK_CMVF is a company primer used to sequence the beginning of the gene, 
RSK_PRIMER is a manually created and synthesised primer used to sequence the middle of 
the gene and RSK_bGHR is a company primer used to sequence the end of the gene. 
Combined use of these primers led to a complete sequence for 3M with the desired 
mutations and no additional mutations. Red box highlights the mutation.  
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Figure 3.2.3 Multiple sequence alignments of RSK4 mutant 4M.   
Site directed mutagenesis was performed on RSK4 in a thermocycler. The mutated DNA 
was amplified, purified and sent to Eurofins for sanger sequencing. Upon return sequences 
were analysed and manipulated. RSK_SEQ is the RSK DNA sequence obtained from 
uniprot, RSK_CMVF is a company primer used to sequence the beginning of the gene, 
RSK_PRIMER is a manually created and synthesised primer used to sequence the middle of 
the gene and RSK_bGHR is a company primer used to sequence the end of the gene. 
Combined use of these primers led to a complete sequence for 4M with the desired 
mutations and no additional mutations. Red box highlights the mutation.  
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3.3 Luciferase reporter assays determining interactions between RSKs and SRs 
The relationship between SRs and RSKs has been characterised in a few combinations for 
example RSK2 was shown to phosphorylate ERα at Ser167 which enhances its 
transcriptional activity (Clark et al. 2001). To create a comprehensive understanding of all 
relationships between SR and RSKs luciferase reporter assays were performed. This 
technique was carried out in COS-1 cells because they are negative for all steroid receptors. 
The vectors pCDNA 3.1 (+) and PSG5 were both chosen because they are mammalian 
expression vectors thus are applicable for use with the COS-1 cells.  
 
3.3.1 Hormone optimisation experiments of steroid receptors 
Prior to directly investigating the effects of RSKs and SRs, the optimal concentration of each 
hormone was identified. The optimal hormone concentration was set to allow for a sub-
maximal level of receptor activity which would allow for both an increase or decrease in 
activity when investigating the effects of RSKs on said receptors. COS-1 cells were 
transfected with plasmids encoding AR or GR or ERα or PR and their corresponding 
responsive luciferase reporters ERE-LUC in the case of ER or TAT-GRE-EIB-LUC-1(TAT-
LUC) in the case of AR, GR, PR. COS-1 cells were also transfected with a control plasmid 
encoding the gene β-galactosidase PDM-LAC-Z-β-GAL (β-GAL). The cells were incubated 
for 20-24 hours post transfection and treated with either EtOH or a dose range (0-1000nM) 
of the receptors cognate hormone: mibolerone (AR), dexamethasone (GR), oestradiol (ER) 
or progesterone (PR). Receptor activity was measured use luciferase assays and the data 
normalised to β-galactosidase expression.  
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The results show a consistent trend across all the SR hormone optimisation experiments 
(Figure 3.3.1.1 A-D). As hormone concentration increases, SR activity also increases. This 
effect plateaus at the highest concentrations of the hormones. All data points are statistically 
significant when compared to activity of SR without hormone (Figure 3.3.1.1 A-D). From this 
data, it was decided that 1nM MIB, 10nM DEX, 10nM E2 and 1nM PROG would be used for 
future experiments. To confirm successful expression of the steroid receptors, western 
blotting was performed (Figure 3E). AR, ERα and GR expression was confirmed, however 
the PR antibody did not appear to work (data not shown). The AR and GR expression 
increased as hormone concentration was increased. The expression of ERα was present at 
all concentrations, highest expression was seen in response to 0.1nM E2 and was similar at 
1, 10 and 100nM E2. Minimal expression was seen in absence of hormone and at the 
highest concentration of E2 (Figure 3.3.1.1 E). 
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Figure 3.3.1.1 Steroid Receptor activity and expression in response to hormone dose 
range 
COS-1 cells were transfected with expression vectors for (A) AR and TAT-LUC or (B) GR 
and TAT-LUC or (C) ERα and ERE-LUC or (D) PR and TAT-LUC. COS-1 cells were also 
transfected with a β-GAL expression plasmid. Cells were treated with either EtOH or a dose 
range (0.1-1000nM) of (A) mibolerone, (B) dexamethasone, (C) 17-β-oestradiol or (D) 
progesterone for 20-24 hours. SR activity was measured using luciferase and normalised to 
β-GAL activity. Mean of 4 independent duplicates ±SE. T-tests were used to compare 
receptor activity at each hormone concentration to receptor activity in the absence of 
hormone. *P<0.05, **P<0.005, ***P<0.0005. (E) Western blotting was conducted to assess 
AR, ERα and GR expression with β-tubulin included as a loading control.  
C D 
B A 
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3.3.2 RSK DNA optimisation experiments  
Following the hormone optimisation experiments, DNA optimisation experiments were 
undertaken, the optimal concentration of RSK DNA was identified. The optimal DNA 
concentration was set to allow for a sub-maximal level of receptor activity which would allow 
for both an increase or decrease in activity when investigating the effects of PMA on RSK 
induced changes on steroid receptor activity. 
 
3.3.2.1 RSK DNA optimisation experiment of the AR 
COS-1 cells were transfected with plasmid DNA encoding the AR, its corresponding 
responsive luciferase reporter gene TAT-LUC and control plasmid β-GAL. The cells were 
also transfected with different concentrations of RSK DNA plasmid with empty plasmid used 
to ensure that equal concentrations of DNA were transfected. Cells were treated with either 
the control EtOH or 1nM MIB and incubated for 20-24 hours. Receptor activity was 
measured using luciferase assays and normalised to β-GAL expression. 
In the presence of androgen, 200ng RSK1 significantly increased AR activity to 
approximately 450%. RSK2 caused an increase in AR activity at the 100ng concentration. 
RSK3 caused no significant change in AR activity. In contrast to RSK1/2, RSK4 reduced AR 
activity by 20% at the 100ng concentration (Figure 3.3.2.1.1). It was therefore decided that a 
concentration of 100ng of the RSK plasmids would be used for future experiments.  
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Figure 3.3.2.1.1 Androgen Receptor activity in response to varied RSK DNA 
concentrations 
COS-1 cells were transfected with plasmids encoding for the AR, TAT-LUC, β-GAL and 
RSK1-4 and incubated for 20-24 hours. Cells were treated with EtOH or 1nM of Mibolerone 
for 20-24 hours. SR activity was measured using luciferase and normalised to β-GAL 
activity. Mean of 5 independent duplicates ±SE. Two-way ANNOVA test was used to 
compare receptor activity at 100ng and 200ng DNA concentrations to receptor activity at 0ng 
of RSK in the presence of hormone. ***P<0.0005. 
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3.3.2.2 RSK DNA optimisation experiment of the GR 
COS-1 cells were transfected with plasmid DNA encoding the GR, its corresponding 
responsive luciferase reporter gene TAT-LUC and control plasmid β-GAL. The cells were 
also transfected with different concentrations of RSK DNA plasmid with empty plasmid used 
to ensure that equal concentrations of DNA were transfected. Cells were treated with either 
EtOH or 10nM DEX and incubated for 20-24 hours. Receptor activity was measured using 
luciferase assays and normalised to β-GAL expression. 
In the presence of dexamethasone, RSK1 caused a significant increase in GR activity at 
both DNA concentrations. RSK2/3 caused modest increases in GR activity, more noticeably 
seen with RSK3 at the 100ng concentration. RSK4 also caused a significant increase in GR 
activity at the 200ng DNA concentration to approximately 195% (Figure 3.3.2.2.1). It was 
therefore decided that a concentration of 100ng of the RSK plasmids would be used for 
future experiments. 
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Figure 3.3.2.2.1 Glucocorticoid Receptor activity in response to varied RSK DNA 
concentrations 
COS-1 cells were transfected with plasmids encoding for the GR, TAT-LUC, β-GAL and 
RSK1-4 and incubated for 20-24 hours. Cells were treated with EtOH or 1nM of 
Dexamethasone for 20-24 hours. SR activity was measured using luciferase and normalised 
to β-GAL activity. Mean of 4 independent duplicates ±SE. Two-way ANNOVA test was used 
to compare receptor activity at 100ng and 200ng DNA concentrations to receptor activity at 
0ng of RSK in the presence of hormone. *P<0.05, ***P<0.0005. 
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3.3.2.3 RSK DNA optimisation experiment of the ERα 
COS-1 cells were transfected with plasmid DNA encoding the ERα, its corresponding 
responsive luciferase reporter gene ERE-LUC and control plasmid β-GAL. The cells were 
also transfected with different concentrations of RSK DNA plasmid with empty plasmid used 
to ensure that equal concentrations of DNA were transfected. Cells were treated with either 
EtOH or 10nM E2 and incubated for 20-24 hours. Receptor activity was measured using 
luciferase assays and normalised to β-GAL expression. 
In the presence of 17β-estradiol, RSK4 caused a significant decrease in ERα activity at the 
200ng DNA concentrations, to approximately to 25% whilst additional modest decreases 
were caused by RSK1/3 (Figure 3.3.2.3.1). RSK2 caused no significant change in ERα 
activity at both concentrations. Despite the 200ng concentrations causing a more profound 
change in activity to allow for additional changes in later experiments the 100ng 
concentration was chosen. 
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Figure 3.3.2.3.1 Estrogen Receptor alpha activity in response to varied RSK DNA 
concentrations 
COS-1 cells were transfected with plasmids encoding for the ERα, ERE-LUC, β-GAL and 
RSK1-4 and incubated for 20-24 hours. Cells were treated with EtOH or 10nM of 17β-
estradiol for 20-24 hours. SR activity was measured using luciferase and normalised to β-
GAL activity. Mean of 3 independent duplicates ±SE. Two-way ANNOVA test was used to 
compare receptor activity at 100ng and 200ng DNA concentrations to receptor activity at 0ng 
of RSK in the presence of hormone. ***P<0.0005. 
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3.3.2.4 RSK DNA optimisation experiment of the PR 
COS-1 cells were transfected with plasmid DNA encoding the PR, its corresponding 
responsive luciferase reporter gene TAT-LUC and control plasmid β-GAL. The cells were 
also transfected with different concentrations of RSK DNA plasmid with empty plasmid used 
to ensure that equal concentrations of DNA were transfected. Cells were treated with either 
EtOH or 1nM PROG and incubated for 20-24 hours. Receptor activity was measured using 
luciferase assays and normalised to β-GAL expression. 
In the presence of progesterone, RSK1 caused no change to PR activity. RSK2 caused a 
modest increase in PR activity at the 200ng concentration whilst RSK3 caused a significant 
increase in PR activity at the 200ng concentration. RSK4 caused a slight decrease in PR 
activity at the 200ng concentration (Figure 3.3.2.4.1). To remain consistent with other 
receptors it was decided that a concentration of 100ng of the RSK plasmids would be used 
for future experiments. 
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Figure 3.3.2.4.1. Progesterone Receptor activity in response to varied RSK DNA 
concentrations 
COS-1 cells were transfected with plasmids encoding for the PR, TAT-LUC, β-GAL and 
RSK1-4 and incubated for 20-24 hours. Cells were treated with EtOH or 10nM of 
progesterone for 20-24 hours. SR activity was measured using luciferase and normalised to 
β-GAL activity. Mean of 5 independent duplicates ±SE. Two-way ANNOVA test was used to 
compare receptor activity at 100ng and 200ng DNA concentrations to receptor activity at 0ng 
of RSK in the presence of hormone. ***P<0.0005. 
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3.3.3 PMA induction experiments 
Following the DNA optimisation experiments, experiments directly investigating the effects of 
RSKs on SR activity were undertaken. The RSKs are downstream effectors of the MAPK 
pathway. To promote maximal activation of the overexpressed RSK, the MAPK activator 
Phorbol Miseryl Acetate (PMA) was used. 
 
3.3.3.1 PMA induction experiment of AR 
COS-1 cells were transfected with plasmid DNA encoding the AR, its corresponding 
responsive luciferase reporter gene TAT-LUC and control plasmid β-GAL. The cells were 
also transfected with 100ng of RSK DNA plasmid. Cells were treated with either EtOH or 
1nM MIB, with either 1 µl of PMA or untreated and incubated for 20-24 hours. Receptor 
activity was measured using luciferase assays and normalised to β-GAL expression. 
RSK1/3/4 caused a significant increase in AR activity with RSK1/4 causing the most effect 
increasing AR activity by approximately 6-fold. Whilst RSK1/2/4 caused a significant 
increase in AR activity in the presence of PMA. However, PMA only significantly enhanced 
RSK1 activation of AR whilst modestly enhancing RSK2/4 activation of AR activity and 
slightly reducing RSK3 activation of AR (Figure 3.3.3.1.1)   
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Figure 3.3.3.1.1 Androgen Receptor activity in response to PMA induced RSKs 
COS-1 cells were transfected with plasmids encoding AR, TAT-LUC, β-GAL, RSK1-4 and 
incubated for 20-24 hours. Cells were treated with either EtOH or 1nM of Mibolerone and ± 1 
µl of [PMA]. SR activity was measured using luciferase assays and data normalised to β-
GAL expression. Mean of 5 independent duplicates ±SE. Two-way ANNOVA test was used 
to compare receptor activity to receptor activity and RSK in the presence of hormone, to 
compare receptor activity to receptor activity and RSK in presence of hormone and PMA and 
to compare differences between SR and RSK in the absence/presence of PMA. *P<0.05, 
**P<0.005, ***P<0.0005. 
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3.3.3.2 PMA induction experiment of GR 
COS-1 cells were transfected with plasmid DNA encoding the GR, its corresponding 
responsive luciferase reporter gene TAT-LUC and control plasmid β-GAL. The cells were 
also transfected with 100ng of RSK DNA plasmid. Cells were treated with either EtOH or 
10nM DEX, with either 1 µl of PMA or untreated and incubated for 20-24 hours. Receptor 
activity was measured using luciferase assays and normalised to β-GAL expression. 
RSK2/3 caused a significant increase in GR activity in the absence and presence of PMA, 
whilst RSK1/4 caused a reasonable increase. The addition of PMA modestly enhanced 
RSK2 activation of GR increasing its activity approximately 0.5-fold whilst causing subtle 
changes to RSK1/3/4 (Figure 3.3.3.2.1).   
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Figure 3.3.3.2.1 Glucocorticoid Receptor activity in response to PMA induced RSKs 
COS-1 cells were transfected with plasmids encoding GR, TAT-LUC, β-GAL, RSK1-4 and 
incubated for 20-24 hours. Cells were treated with either EtOH or 10nM of Dexamethasone 
and ± 1 µl of [PMA]. SR activity was measured using luciferase assays and data normalised 
to β-GAL expression. Mean of 5 independent duplicates ±SE. Two-way ANNOVA test was 
used to compare receptor activity to receptor activity and RSK in the presence of hormone, 
to compare receptor activity to receptor activity and RSK in presence of hormone and PMA 
and to compare differences between SR and RSK in the absence/presence of PMA. 
**P<0.005, ***P<0.0005.  
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3.3.3.3 PMA induction experiment of ERα 
COS-1 cells were transfected with plasmid DNA encoding the ERα, its corresponding 
responsive luciferase reporter gene ERE-LUC and control plasmid β-GAL. The cells were 
also transfected with 100ng of RSK DNA plasmid. Cells were treated with either EtOH or 
10nM E2, with either 1 µl of PMA or untreated and incubated for 20-24 hours. Receptor 
activity was measured using luciferase assays and normalised to β-GAL expression. 
RSK4 causes a significant decrease in ERα activity in both the absence and presence of 
PMA whilst RSK1 causes a minor decrease in ERα activity in the absence of PMA. The 
addition of PMA causes no significant change in ERα activity but does cause a moderate 
increase in activity for RSK1/4 returning ERα activity towards basal activity (Figure 
3.3.3.3.1).   
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Figure 3.3.3.3.1 Estrogen Receptor α activity in response to PMA induced RSKs 
COS-1 cells were transfected with plasmids encoding ER, ERE-LUC, β-GAL, RSK1-4 and 
incubated for 20-24 hours. Cells were treated with either EtOH or 10nM of 17β-estradiol and 
± 1 µl of [PMA]. SR activity was measured using luciferase assays and data normalised to β-
GAL expression. Mean of 7 independent duplicates ±SE. Two-way ANNOVA test was used 
to compare receptor activity to receptor activity and RSK in the presence of hormone, to 
compare receptor activity to receptor activity and RSK in presence of hormone and PMA and 
to compare differences between SR and RSK in the absence/presence of PMA. *P<0.05, 
**P<0.005. 
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3.3.3.4 PMA induction experiment of PR 
COS-1 cells were transfected with plasmid DNA encoding the PR, its corresponding 
responsive luciferase reporter gene TAT-LUC and control plasmid β-GAL. The cells were 
also transfected with 100ng of RSK DNA plasmid. Cells were treated with either EtOH or 
10nM E2, with either 1 µl of PMA or untreated and incubated for 20-24 hours. Receptor 
activity was measured using luciferase assays and normalised to β-GAL expression. 
In the absence of PMA RSK3 causes a significant increase in PR whilst RSK2 causes a 
minor reduction in PR activity. The addition of PMA significantly enhances the reduction in 
RSK3 activation of PR returning activity towards basal levels, additionally RSK1/2/4 
activation of PR activity is repressed marginally in the presence of PMA. (Figure 3.3.3.4.1). 
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Figure 3.3.3.4.1 Progestrone Receptor activity in response to PMA induced RSKs 
COS-1 cells were transfected with plasmids encoding PR, TAT-LUC, β-GAL, RSK1-4 and 
incubated for 20-24 hours. Cells were treated with either EtOH or 10nM of progesterone and 
± 1 µl of [PMA]. SR activity was measured using luciferase assays and data normalised to β-
GAL expression. Mean of 7 independent duplicates ±SE. Two-way ANNOVA test was used 
to compare receptor activity to receptor activity and RSK in the presence of hormone, to 
compare receptor activity to receptor activity and RSK in presence of hormone and PMA and 
to compare differences between SR and RSK in the absence/presence of PMA. **P<0.005, 
***P<0.0005.  
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3.3.4 Phospho-mimetic experiments 
Following the PMA induction experiments, experiments investigating the activation state of 
the endogenous MAPK pathway for each SR were undertaken. This was done by creating 
constitutively active phosho-mimetic mutants of the RSKs at their N-terminal phosphorylation 
site which were compared to wildtype to infer the activation state. 
MIB and incubated for 20-24 hours. Receptor activity was measured using luciferase assays 
and normalised to β-GAL expression. 
3.3.4.1 Phospho-mimetic experiment of AR 
COS-1 cells were transfected with plasmid DNA encoding the AR, its corresponding 
responsive luciferase reporter gene TAT-LUC and control plasmid β-GAL. The cells were 
also transfected with 100ng of RSK DNA plasmid or 100ng of RSK-Mutant (RSKM) DNA. 
Cells were treated with either EtOH or 1nM MIB and incubated for 20-24 hours. Receptor 
activity was measured using luciferase assays and normalised to β-GAL expression (Figure 
3.3.4.1.1). 
Wildtype RSK4 causes a significant increase in AR activity by approximately 2-fold, whilst 
RSK2 causes a moderate increase AR activity. Similarly, 4M causes a significant increase in 
AR activity whilst 2M represses the activity AR. Wildtype RSK2 causes significantly higher 
activity on the AR than its mutant counterpart suggesting the endogenous MAPK pathway is 
sufficiently active (Figure 3.3.4.1.1). 
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Figure 3.3.4.1.1 Androgen Receptor activity in response to RSKs and RSK mutants 
COS-1 cells were transfected with plasmids encoding AR, TAT-LUC, β-GAL, either RSK2-4 
or RSK2-4M and incubated for 20-24 hours. Cells were treated with either EtOH or 1nM of 
mibolerone. SR activity was measured using luciferase assays and data normalised to β-
GAL expression. Mean of 4 independent duplicates ±SE. Two-way ANNOVA test was used 
to compare SR to SR with RSKs or RSK mutants in the presence of hormone and to 
compare the RSKs to their corresponding mutants in the presence of hormone. *P<0.05, 
***P<0.0005.  
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3.3.4.2 Phospho-mimetic experiment of GR 
COS-1 cells were transfected with plasmid DNA encoding the GR, its corresponding 
responsive luciferase reporter gene TAT-LUC and control plasmid β-GAL. The cells were 
also transfected with 100ng of RSK DNA plasmid or 100ng of RSK-Mutant (RSKM) DNA. 
Cells were treated with either EtOH or 10nM DEX and incubated for 20-24 hours. Receptor 
activity was measured using luciferase assays and normalised to β-GAL expression (Figure 
3.3.4.2.1). 
Wildtype RSK2/4 cause a significant increase in GR activity, RSK4 causing the most effect, 
increasing GR activity by approximately 2-fold. Additionally, 4M caused a significant increase 
in GR activity. Wildtype RSK2 induces a significantly higher activity on the AR than its 
mutant counterpart suggesting the endogenous MAPK pathway is active sufficiently (Figure 
3.3.4.2.1). 
  
126 
 
 
Figure 3.3.4.2.1. Glucocorticoid Receptor activity in response to RSKs and RSK 
mutants 
COS-1 cells were transfected with plasmids encoding GR, TAT-LUC, β-GAL, either RSK2-4 
or RSK2-4M and incubated for 20-24 hours. Cells were treated with either EtOH or 10nM of 
dexamethasone. SR activity was measured using luciferase assays and data normalised to 
β-GAL expression. Mean of 4 independent duplicates ±SE. Two-way ANNOVA test was 
used to compare SR to SR with RSKs or RSK mutants in the presence of hormone and to 
compare the RSKs to their corresponding mutants in the presence of hormone. *P<0.05, 
***P<0.0005.  
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3.3.4.3 Phospho-mimetic experiment of ERα 
COS-1 cells were transfected with plasmid DNA encoding the ERα, its corresponding 
responsive luciferase reporter gene ERE-LUC and control plasmid β-GAL. The cells were 
also transfected with 100ng of RSK DNA plasmid or 100ng of RSK-Mutant (RSKM) DNA. 
Cells were treated with either EtOH or 10nM E2 and incubated for 20-24 hours. Receptor 
activity was measured using luciferase assays and normalised to β-GAL expression (Figure 
3.3.4.3.1). 
All Wildtype RSKs caused no significant change in ERα activity but RSK4 causes a 
reasonable decrease in ERα activity by approximately 0.5-fold. All RSK mutants caused a 
significant decrease in ERα. However, there are no significant differences between the 
wildtype and mutant RSKs suggesting the endogenous pathway is sufficiently active (Figure 
3.3.4.3.1). 
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Figure 3.3.4.3.1 Estrogen Receptor alpha activity in response RSKs and RSK mutants 
COS-1 cells were transfected with plasmids encoding ERα, ERE-LUC, β-GAL, either RSK2-
4 or RSK2-4M and incubated for 20-24 hours. Cells were treated with either EtOH or 10nM 
of 17β-estradiol. SR activity was measured using luciferase assays and data normalised to 
β-GAL expression. Mean of 4 independent duplicates ±SE. Two-way ANNOVA test was 
used to compare SR to SR with RSKs or RSK mutants in the presence of hormone and to 
compare the RSKs to their corresponding mutants in the presence of hormone. **P<0.005. 
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3.3.4.4 Phospho-mimetic experiment of PR 
COS-1 cells were transfected with plasmid DNA encoding the PR, its corresponding 
responsive luciferase reporter gene TAT-LUC and control plasmid β-GAL. The cells were 
also transfected with 100ng of RSK DNA plasmid or 100ng of RSK-Mutant (RSKM) DNA. 
Cells were treated with either EtOH or 1nM PROG and incubated for 20-24 hours. Receptor 
activity was measured using luciferase assays and normalised to β-GAL expression (Figure 
3.3.4.4.1). 
Wildtype RSK3/4 cause a significant increase in PR where as RSK2 causes a marginal 
decrease in PR activity. 2M/4M caused a significant decrease in PR and 3M causes a 
moderate decrease in PR activity. Wildtype RSK3/4 cause a significantly higher increase in 
PR activity than their mutant counterparts suggesting the endogenous pathway is sufficiently 
active (Figure 3.3.4.4.1). 
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Figure 3.3.4.4.1 Progesterone Receptor activity in response to RSKs and RSK mutants 
COS-1 cells were transfected with plasmids encoding PR, TAT-LUC, β-GAL, either RSK2-4 
or RSK2-4M and incubated for 20-24 hours. Cells were treated with either EtOH or 1nM of 
progesterone. SR activity was measured using luciferase assays and data normalised to β-
GAL expression. Mean of 4 independent duplicates ±SE. Two-way ANNOVA test was used 
to compare SR to SR with RSKs or RSK mutants in the presence of hormone and to 
compare the RSKs to their corresponding mutants in the presence of hormone. *P<0.05, 
***P<0.0005.  
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3.3.5 Summary of Luciferase reporter assays  
(Table 3.3.5.1) shows a summary of the RSK induced changes in SR activity and the 
significant differences between the pairs of data  
Table 3.3.5.1 Summary of RSK effects on Steroid Receptor activity.  
↑ represents an increase in SR activity 200≥, ↑↑ represents an increase in SR activity <500, 
↑↑↑ represents an increase in SR activity >500. ↓ represents a decrease in SR activity ≥75, 
↓↓ represents a decrease in SR activity ≥50, ↓↓↓ represents a decrease in SR activity <50. 
B.L means basal levels of activity.  
AR RSK1 RSK2 RSK3 RSK4 
DNA ↑↑ ↑ ↑ ↓ 
-PMA ↑↑↑ * ↑↑ 
 
↑↑  ↑↑↑  
+PMA ↑↑↑ ↑↑↑ ↑↑ ↑↑↑ 
WT  ↑ * ↑  ↑↑  M ↓↓ ↑ ↑↑ 
     
GR RSK1 RSK2 RSK3 RSK4 
DNA ↑ ↑ ↑ ↑ 
-PMA ↑  ↑ 
 
↑↑  ↑  
+PMA ↑ ↑↑ ↑↑ ↑ 
WT  ↑↑ * ↑  ↑↑  M ↑ ↑ ↑↑ 
     
ERα RSK1 RSK2 RSK3 RSK4 
DNA ↓↓ ↑ ↓ ↓↓↓ 
-PMA ↓↓ 
 
↓  ↑  ↓↓↓ 
 
+PMA B.L B.L ↓ ↓ 
WT  ↓↓  ↓↓  ↓↓  
M ↓↓ ↓↓ ↓↓ 
     
PR RSK1 RSK2 RSK3 RSK4 
DNA ↑ ↑ ↑↑ ↓ 
-PMA ↑  ↑  ↑↑ * ↑  +PMA ↑ ↓↓ ↑ ↑ 
WT  ↓ 
 
↑ * ↑ * M ↓↓ ↓ ↓↓ 
     
 
There is a common condition across all three experiments, 100ng of RSK DNA with the set 
concentration of hormone relative to its receptor. It can be seen from this table and within the 
data, there are some discrepancies with the RSK effects induced on the same SR across the 
three experiments which could question the reproducibility. There are also examples which 
show adverse effects from the mutant RSK which could question the constitutive activation 
of the RSK mutants, especially when comparing to +PMA.  
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Chapter 4 - Discussion 
The RSKs are a group of Serine/Threonine kinases which are the terminal effectors of the 
MAPK pathway. This pathway and by extension the RSKs, regulates and drives essential 
cellular processes such as cell proliferation, cell survival and cell motility. Cancerous cells 
can exploit this pathway to favour growth and proliferation, resulting in RSKs being 
implicated in several cancerogenic processes. Specifically, the RSKs have roles in BCa and 
PCa progression, which are tumours driven by steroids and their respective steroid 
receptors. Unfortunately, the number of characterised interactions between RSKs and the 
steroid receptors is limited.  
Due to the level of similarity, RSK1 and RSK2 have been considered the prototypical RSKs 
and RSK3 and RSK4 have been largely neglected. However, an increasing number of 
studies have indicated that RSK isoform function differently and have sometime opposing 
roles in different cancer types. In fact, an increasing number of evidences suggest that 
RSK1/2 are not always inducing cancer growth and RSK3/4 are not always tumour 
suppressor genes. For example, RSK2 was shown to promote head and neck squamous cell 
carcinoma (HNSCC) metastasis whereas RSK1 has no effect on HNSCC metastasis (Kang 
et al. 2010), but was shown to negatively regulate metastasis in non-small cell lung cancer 
(Lara et al. 2011). Additionally, RSK3/4 facilitate proliferation in BCa through inhibition of the 
apoptotic pathway in response to PI3K inhibitors (Serra et al. 2013). This suggests that the 
effect RSKs have varied activities dependent on tissue and/or cancer type. Considering the 
number of cancer types the RSKs are implicated in and the varied effects they have on 
different tissue types, this project aimed to fill the lack of knowledge regarding the 
relationships between the RSKs and SRs. Through this project the use of recombinant DNA 
techniques enabled a series of reporter assays to show changes in SR activity in response 
to the RSK signalling. RSKs genes were amplified and incorporated into the mammalian 
expression vector PCDNA 3.1+ with a HA tag, which was successful for RSK2/3 (Figure 
3.1.1 and 3.1.2). This was not necessary for RSK1/4 as synthetic clones were purchased. 
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Site directed mutagenesis was used to create mutant RSKs, which was successful for 
RSK2/3/4 (Figure 3.2.1). Luciferase experiments were performed on mammalian COS-1 
cells as they do not express SRs. The hormone optimisation experiments (Figure 3.3.1) 
were used to determine the concentration of hormone to use for each SR which would allow 
for a suitable increase or decrease in SR activity when under the influence of the RSKs. 
1nM, 10nM, 10nM and 1nM were chosen for AR, GR, ERα and PR respectively. The DNA 
optimisation experiments (Figures 3.3.2.1-4.1) were used to determine the concentration of 
DNA to use for all RSKs which would allow for a suitable increase or decrease in SR activity 
(100ng was chosen). Cells were treated with PMA (Figures 3.3.3.1-4.1) to induce activation 
of all RSKs expressed thus to determine if the endogenous MAPK pathway was active 
sufficiently to activate all RSKs over-expressed within the COS-1 cells. The mutagenesis 
experiments (Figures 3.3.4.1-4.1) were used to determine if the phosphorylation state of the 
RSKs is necessary for SR activation. Overall, all RSK isoforms cause an increase in AR and 
GR activity despite not all being statistically significant, whereas RSK4 significantly 
decreased ERα activity and RSK3 significantly increased PR activity.  
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4.1 – The Androgen Receptor 
The AR plays a significant role in both PCa and BCa. In PCa activated AR transcribes genes 
which promote cell growth and survival. As such, PCa is often treated with anti-androgen 
treatments, which block the formation and circulation of AR ligand (Litwin & Tan 2017). 
However, a significant proportion of patients relapse over time by developing Castration 
Resistant Prostate Cancer (CRPC), which occurs by several proposed mechanisms all of 
which revolve around the AR (Tan et al. 2015). BCa is predominantly ERα driven, however 
there is also evidence of the AR contributing to BCa. The AR has been shown to increase 
tamoxifen resistance in ERα+ BCa (De Amicis et al. 2010) and be the driving force in ERα-/- 
BCa. The AR drives a positive feedback loop, regulating the activity of ERK and the RSKs to 
regulate gene expression and drive growth (Chia et al. 2015). Unfortunately, resistance to 
anti-estrogen therapy occurs often in BCa. However, treatment with enzalutamide was 
shown to decrease the proliferation of both ERα+/+ and ERα-/- BCa highlighting the 
significant role that AR plays (Cochrane et al. 2014).  
From this project the luciferase assays showed the effect the RSKs have on the AR. 
Although there are some discrepancies, considering the data across all experiments it is 
apparent that RSK1-4 cause an increase in AR activity. The DNA optimisation experiments 
(Figure 3.3.2.1.1) showed that RSK1 causes a significant increase in AR activity. The PMA 
induction experiments (Figure 3.3.3.1.1) showed that RSK1/3/4 cause a significant increase 
in AR activity in the absence of PMA whilst RSK2 causes a significant increase in AR activity 
in the presence of PMA. However, only RSK1 caused a statistically significant difference 
between the +PMA and -PMA conditions suggesting that the endogenous MAPK pathway is 
sufficiently active. The phospho-mimetic experiments using RSK mutants (Figure 3.3.4.1.1) 
showed that the RSK4 causes a significant increase in AR activity. Additionally, when 
comparing the wildtype RSK2 with 2M there is a statistically significant difference between 
the two conditions. In conjunction with this, when considering all RSK2 experiments with 
comparable conditions there is a relatively similar luciferase output however the 2M output is 
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considerably lower. This could suggest that the mutation did not cause constitutive 
activation. In fact, treatment with PMA generates a signal 7-fold higher than the mutant, 
while we would have expected a similar or higher signal by a constitutively active mutant.  
Although the data illustrated the effect of the RSKs on SR activity there is no insight by 
which mechanism these effects are caused. When considering the AR and the RSKs this 
could occur in two ways, (i) direct regulation via phosphorylation of the AR, or (ii) indirect 
regulation via the phosphorylation of another protein which in turn regulates the AR. (i) It is 
well established that AR can be directly phosphorylated by a several kinases to regulate 
gene expression. The AR has been shown to be phosphorylated at the Serine residues 16, 
81, 94, 213, 256, 293, 308, 424, 515, 578, 650, 791 and on Threonine residue 282 (Gioeli & 
Paschal 2012). CDK9 phosphorylates the AR on Ser81 which in turn causes changes in 
gene expression and increased cell growth in both LHS and LaCP4 cell lines. Most AR 
canonical target genes remained unchanged or had insignificant changes in gene 
expression when Ser was substituted for Ala. However, two genes TMPRSS2 and ORM1, 
had reduced transcription when compared to the AR wt. This suggests that the CDK9 
phosphorylation of Ser81 regulates the AR selectivity of promoters and transcriptional 
program (Gordon et al. 2010). Conversely, in LNCaPs and C4-2 PCa cell lines, CDK1 
phosphorylates the AR on Ser81 and increases AR expression but had no effect on its 
transcriptional activity. Furthermore, CDK1 increases the stability of the AR by an unknown 
mechanism, which could potentially be due to an additional phosphorylation. As such, CDK1 
activation would support CRPC, as an overall increase in AR is achieved, thus increasing 
sensitivity to ligand (Chen et al. 2006). Additionally, CDK7 was shown to phosphorylate the 
AR on Ser515. This phosphorylation is caused by recruitment of the transcription factor 
complex TFIIH, which contains a CDK7 subunit, to the PSA promoter. After phosphorylation 
further coactivators are recruited, transcription occurs and the AR gets ubiquitinated for 
degradation to ensure cyclical activation and transcription of the gene (Chymkowitch et al. 
2011). (ii) Previous data show that RSK1 regulates the AR by in an indirect mechanism. 
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LNCaP cells were androgen deprived and treated with enzalutamide causing activation of 
RSK1, which in turn activates the transcription factor YB1. YB1 then induces the 
transcriptional activity of the AR. This then went on to contribute to CRPC (Shiota et al. 
2014). There is also evidence to show RSK2 involvement in PCa however the mechanism 
was not fully elucidated. RSK2 causes an increase in expression of the PCa diagnostic 
marker PSA. The increase in PSA is caused by association of RSK2 with the transcriptional 
coactivator p300. Through RNAi it was shown that the AR was involved, but the exact 
mechanism was not characterised (Clark et al. 2005). 
While no direct RSKs phosphorylation of AR has been reported, there is a possibility of cross 
talk between the CDKs and the RSKs. RSK2 has been shown to indirectly regulate CDK2 by 
phosphorylating and localising P27KIP1 to the cytoplasm which then allows for the formation 
of A/E CKD2 complexes and progression of the cell cycle (Fujita et al. 2003). While it is 
possible to hypothesise that the RSKs is regulating the AR an indirect mechanism (see 
future work) acting on other transcription factor or kinase, it is unlikely. Despite the previous 
data showing indirect regulation, the increases in AR activity were so large that it is unlikely 
to be via indirect regulation, which would only increase endogenous AR expression or could 
only moderately increase over-expressed AR activity.  
These results also show that the RSKs are a potential therapeutic target for BCa and PCa. 
In fact, RSK-YB1 signalling was shown to be active in Triple Negative Breast Cancer 
(TNBCa). Human Mammary Epithelial Cells (HMECs) were treated with RSK inhibitors BI-
D1870, the next generation inhibitor LJI308, and Luteolin to reveal promising results. LJI308 
was most effective repressing growth and causing apoptosis in the HMECs, in addition the 
inhibitor targeted transformed cells preferentially over parental HMECs which observed little 
effect from the inhibitor, supporting RSKs as a therapeutic target for TNBCa (Davies et al. 
2015). To build on this the RSK-YB1 signalling was also observed in the PCa cell line 
LNCaP therefore it would follow that RSK inhibitors would also show promise in PCa. Finally, 
137 
 
when considering that all the RSKs induced an increase in AR activity it could be possible 
that phosphorylating the AR is a redundant function across all the isoforms.  
4.2 – The Glucocorticoid Receptor 
The GR is implicated in diseases such as Chron’s disease, Asthma, Arthritis and several 
more. Glucocorticoids (GCs) have been used for decades as anti-inflammatory drugs and to 
control autoimmune diseases. The GR is ubiquitously expressed but retains cell type 
dependent specificity, however, this means that adverse systemic side effects can occur. In 
addition, the development of GC resistance (GCR) can arise from long term use GC based 
drugs (Caratti et al. 2015). The GR is also implicated in Cancer but has adverse effects 
dependent on the cancer type. For example, the GR is responsible for activating the 
apoptotic program in Haematological Malignancies and aids prevention of skin tumour 
promotion. Conversely, the GR has been shown to repress chemotherapy-induced apoptosis 
in BCa and Skin Cancer (SCa). Furthermore, PCa GCs are used for inhibition as part of 
chemotherapy in advanced CRPC, but PCa patients which have been on Androgen 
deprivation therapy show increased proliferation (Sundahl et al. 2016).  
Results from this project showed the effect the RSKs have on the GR. The DNA optimisation 
experiments (Figure 3.3.2.2.1) show that RSK1/4 cause a significant increase in GR activity. 
The PMA induction experiments (Figure 3.3.3.2.1) show that RSK2/3 cause a significant 
increase in GR activity and that the endogenous pathway of the COS-1 cells was active 
sufficiently to activate all expressed RSKs. The phospho-mimetic experiments (Figure 
3.3.4.2.1) show that RSK2/4 cause a significant increase in GR activity. Like the AR, RSK2 
induces a statistically significant difference between wildtype and its mutant counterpart 
suggesting that the RSKs may not be constitutively active. Although there are some 
discrepancies, considering the data across all experiments it is apparent that RSK1-4 cause 
an increase in GR activity despite some contradictory results between experiment types.  
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Although the data illustrated the effect of the RSKs on GR activity, there is no insight by 
which mechanism these effects are caused. Like the conclusion drawn for AR, when 
considering the GR and the RSKs interplay, this could occur in two ways, (i) direct regulation 
(ii) or indirect regulation. To present there is no data concerning the RSKs relationship with 
the GR. However, how other proteins regulate the GR can show insight as to how the RSKs 
might also regulate the GR. (i) GR can be phosphorylated in several sites, some of which 
have been identified on Ser113, Ser134, Ser141, Ser203, Ser211, Ser226, and Ser404 
(Ismaili & Garabedian 2004). Additionally, potential phosphorylation sites which have not 
been tested for function are Ser45, Ser234 and Ser267 (Vandevyver et al. 2014). A 
CDK5/p35 complex was shown to bind to the LBD and then phosphorylate the GR at Ser203 
and Ser211, both of which are in the AF1 domain of the NTD. These phosphorylations cause 
a halt in recruitment of transcriptional co-factors to GR when it is bound to Glucocorticoid 
Responsive Elements (GREs) of MMTV in HCT116 and COS-7 cells and SGK promoters in 
rat neuronal cortical cells. This further illustrates the diversity of GR signalling and supports 
the premise of regulation of genes and promoters is cell type specific (Kino et al. 2007). 
GSK3-β was also shown to phosphorylate the GR at Ser404. This phosphorylation resulted 
in a large-scale change in transcriptional activity of the GR. For example, the gene IL-4 was 
expressed 2-fold higher and the gene STAT4 was expressed 6-fold higher when Ser404 was 
phosphorylated under hormone conditions than when under normal cellular conditions 
(Galliher-Beckley et al. 2008). c-Jun N-terminal Kinase (JNK) was also shown to 
phosphorylate the GR at Ser226. This phosphorylation causes the early export of GR from 
the nucleus once withdrawal of ligand occurs. This export then causes inhibition of 
transcription of GR target genes (Itoh et al. 2002). Similarly, p38, once activated by MKK3, 
was also shown to phosphorylate the GR at Ser211. These events were induced by the GR 
mediated apoptosis pathway which resulted in apoptosis of lymphoid cells. The Ser211 
phosphorylation in this case was shown to induce the GRE-dependent transcription of the 
p38 kinase MKK3 (Miller et al. 2005). (ii) However, at this stage, we cannot exclude that 
RSKs increased activation of GR it could be from an indirect mechanism. However, 
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differently from AR, there are no available data regarding transcription factors regulating GR 
expression, which are targeted by RSKs. These results again provide further evidence 
contesting the previous perception of set roles of the RSKs. 
Although not directly linked to GR activity, studies have investigated the effect of RSK 
inhibitors on SCa, which, as mentioned before, is a type of cancer driven by GR. Nearly 
every relapse of melanoma has a mutation within B-Raf which causes constitutive activation 
of the MAPK pathway, which in turn activates cell survival and promotes resistance to MAPK 
inhibitors. Inhibition of the RSKs with BI-D1870 and LJH-685 caused a reduction in growth of 
the drug-resistant melanoma cells, which becomes sensitive again to the MAPK inhibitors. It 
is not known if this positive effect is achieved through indirect inhibition of GR, which is 
however a hypothesis worth exploring considering the preliminary data collected in this 
study. However, this shows promise for the use of RSK inhibitors independently and in 
combination with MAPK inhibitors for the treatment of melanomas and advanced resistant 
melanomas (Kosnopfel et al. 2017).  
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4.3 – The Estrogen Receptor α 
The ERα has been shown to participate in BCa, OvCa and PCa (Jia et al. 2015). ERα is 
pivotal in BCa as it drives tumorigenesis and disease progression. Anti-estrogen therapy is 
the primary treatment for BCa to reduce hormone activated proliferation, the use of 
aromatase inhibitors is also implemented to reduce the conversion of androgens to 
estrogens. However, often patients experience relapses due to resistance to the therapy 
(Droog et al. 2013). In OvCa ERα drives cell proliferation, invasion and therapy resistance. 
Anti-estrogen therapy would seem favourable however the response is modest (Chan et al. 
2014). The ERαα also contributes to carcinogenesis in PCa by producing E2 inside the cells 
which unbalances hormone concentrations in the cellular environment and drives growth. 
Anti-estrogen therapy has been shown to be effective in PCa early stages (Ricke et al. 
2007).  
Results from this project showed the effect the RSKs have on the ERα. Differently from AR 
and GR, ERα activity seems to be RSK-isoform dependent. The DNA optimisation 
experiments (Figure 3.3.2.3.1) show that RSK4 causes a significant decrease in ERα 
activity. The PMA induction experiments (Figure 3.3.3.3.1) show that RSK4 causes a 
significant decrease in ERα activity in the absence and presence of PMA. The phospho-
mimetic experiments (Figure 3.3.4.3.1) show that 2/3/4M cause a significant decrease in 
ERα activity whilst all wildtype RSKs cause a moderate reduction in ERα activity. 
Considering all of the data RSK4 causes a significant decrease in ERα activity whilst 
RSK1/3 may need further investigation as they caused a moderate decrease in ERα activity, 
but they were not statistically significant.  
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The conflicting results of RSK2 on ERα activity will require further attention (see future 
work), considering that several studies have shown direct interaction of RSK2 with ERα. 
From literature it has been shown that RSK2 binds to the LBD associating with residues 326-
394 and then phosphorylate the ERα at Ser167, enhancing the AF1 transcriptional activity 
(Clark et al. 2001). However, this conflicts with the data obtained (Figure 3.3.2.3.1). RSK1/2 
were also shown to phosphorylate ERα at Ser167 and Ser118, both of which enhanced the 
transcriptional activity of AF1 (Joel et al. 1998), which again contradicts with the results 
presented here. This was shown to be through a co-operation between the MAPK pathway 
and the mTORC pathway which leads to the development of therapy resistance, with Ser167 
phosphorylation being diagnostic to determine whether to proceed with endocrine or anti-
estrogen therapy (Yamnik & Holz 2010). Data on RSK3 are in line with previous observation 
that showing that RSK3 is a tumour suppressor in OvCa. RSK3 was shown to be 
monoallelically expressed in normal ovary cells but this single expression resulted in a loss 
of function in cancer cells. Reintroduction of RSK3 into cancer cell lines resulted in reduced 
proliferation, suppressed growth, G1 cell cycle arrest leading to apoptosis. The mechanism 
by which this occurred was not elucidated (Bignone et al. 2007). Considering that ERα and 
RSK3 have been implicated in OvCa it could be possible that these two proteins interact to 
mediate the effects seen, especially in conjunction with the results where RSK3 caused a 
decrease in ERα activity. Similarly RSK4 was shown to possess tumour suppressor 
properties in breast adenocarcinoma cells as downregulation by several methods lead to 
cancer cell proliferation and invasion (Zhu et al. 2015) which coincides with the data 
presented. 
It is therefore tempting to speculate that both RSK3 and RSK4 play a tumour suppressor 
function in ERα-driven cancer by interacting directly with ERα.  
This is further reinforced by studies that shows how different kinases regulates ERα by 
directly phosphorylating it. PKCθ was shown to regulate the expression of ERα via an 
indirect mechanism. In normal mammary gland cells PKCθ and AKT activity is low which 
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causes the ERα/p27KIP transcription factor FOXO3a to remain unphosphorylated and 
transcribe the ERα and p27KIP. In turn the ERα then repressed the transcription factor NFkB 
c-Rel and p27KIP to inhibits G1/S transition. However, in most primary BCas NFkB c-Rel is 
upregulated by PKCθ activation which in turn phosphorylated AKT which then 
phosphorylates FOXO3a causing it translocation to the cytoplasm. The translocation of 
FOXO3a results in repression of the ERα which can then no longer repress NFkB c-Rel. 
Additionally, it decreases in expression of P27KIP and alleviates cell cycle arrest in G1. NFkB 
c-Rel is then able to transcribe its target genes c-MYC, Cyclin D1, BCL-XL, which promote 
cell growth and cell survival, and NFkB RelB which promotes an invasive cancer phenotype 
(Belguise et al. 2007). Furthermore, the c-Rel transcriptional product RelB negatively 
regulates the expression of ERα in most primary ERα positive BCa’s. RelB transcribes BCL-
2 which in turn associates and activates Ras leads to the expression of a zinc finger 
repressor Blimp1. Blimp1 then binds upstream of a ERα promoter and reduces expression. 
The reduction of ERα expression in turn results in reduced transcription of the relevant target 
genes which encode E-cadherin and γ-catenin which promotes cancer migration (Wang et 
al. 2009). There is also evidence of additional direct phosphorylations to the ERα to regulate 
its transcriptional activity. In response to hormone it has been shown that ERα is 
phosphorylated on Ser104 and Ser106 by CDK2 both of which reside in the AF1 domain and 
enhances its transcriptional activity (Rogatsky et al. 1999). Additionally, Protein Kinase A 
(PKA) was shown to phosphorylate the ERα on Ser236 within the DNA binding domain 
which negatively regulates transcription by inhibiting ERα binding to DNA (Chen et al. 1999). 
AKt was also shown to phosphorylate the ERα on Ser167 within its AF1 domain and cause 
transcription of the PS2 gene, BCL-2 and macrophage inhibitory cytokine to contribute to 
chemotherapy resistance (Campbell et al. 2001).  
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4.4 – The Progesterone Receptor 
The PR has primarily been implicated in BCa. PR plays a key role in BCa and in most cases 
possesses tumour suppressing properties. For example, progesterone treatment has been 
shown to reduce proliferation in BCa cell lines and synthetic progestogens have been shown 
to oppose estrogen stimulate growth in ERα+/PR+ xenografts. Additionally, exogenous 
expression of PR was shown to block ERα mediated proliferation and transcription. Due to 
such involvement of PR in regulating the effects of ERα it is used for a positive prognostic 
marker for disease outcome, with higher expression in early stage disease being highly 
correlated with increased responsiveness to endocrine therapy (Mohammed et al. 2015).  
The data obtained from the luciferase assays showed the effect the RSKs have on PR. The 
DNA optimisation experiments (Figure 3.3.2.4.1) show that RSK3 causes a significant 
increase in PR activity. The PMA induction experiments (Figure 3.3.3.4.1) show that RSK3 
causes a significant increase in PR activity. Furthermore, RSK3 generated a statistically 
significant higher signal without PMA treatment than in its presence in addition to RSK1/2/4 
following the same pattern in a modest manner. This suggests that somehow PMA treatment 
has a negative effect on PR activity and that the endogenous MAPK pathway is sufficiently 
active. The mutant experiments (Figure 3.3.4.4.1) show that wildtype RSK3/4 caused a 
significant increase in PR activity and all three mutant isoforms showed a major decrease in 
PR activity, of which 2/4M were statistically significant. Considering this in conjunction with a 
statistical significance being present between RSK3/4 and their mutant counterparts it again 
suggests that the mutants are not constitutively active, and the endogenous MAPK pathway 
was able to fully activate the over-expressed RSKs.  When considering all the data RSK3 
causes a significant increase in PR activity whilst RSK4 may require some further 
investigation.  
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There are several discrepancies within the different experiments, which do not fully clarify 
the role of RSKs in PR activity. It is however possible to detect a link between RSKs and PR 
activity, which is novel, since no studies have focused on the relationship between RSK and 
PR. Unlike the other SRs, the PR has four basal phosphorylations which occur in a ligand 
independent manner, but are increased after hormone treatment, Ser81, Ser162, Ser190 
and Ser400. These phosphorylations results in the transcription of a small set of genes 
(Abdel-Hafiz & Horwitz 2014). CDK2 was shown to phosphorylate the PR on Ser400 
independently of hormone, being the kinases responsible for this basal phosphorylation. This 
resulted in the increased localisation of the PR to the nucleus and increased its 
transcriptional activity. However, the phosphorylation was increased in response to hormone 
and mitogens (Pierson-Mullany & Lange 2004). CDK2 has also been shown to 
phosphorylate the PR at several additional positions Ser25, 162, and 190, 213, 294, 554, 
676 and Thr430 highlighting its highly regulatory role with PR. Of these Ser190, 554 and 676 
have been shown to regulate the transcriptional activity of PR in a hormone dependent 
manner (Hagan et al. 2012). In contrast, it was shown that elimination of CDK2 
phosphorylation sites resulted in minimal change to PR activation. Additionally, it was shown 
that PR interacts with cyclin A and recruits CDK2 to form the cyclin A/CDK2 at PR 
responsive promoters to facilitate transcription. This was also dependent on recruitment of 
Steroid receptor coactivator 1 (SRC-1) and its phosphorylation state to acetylate DNA at the 
promoter (Narayanan et al. 2005). Although CDK2 was shown to phosphorylate several sites 
on the PR, these sites are not exclusively phosphorylated by it. Casein Kinase II (CK2) was 
shown to phosphorylate PR on Ser81 both in the presence of hormone and in the absence 
of hormone during the cell cycle G1/S transition point. The phosphorylation in the presence 
of hormone was however, considerably faster. Through mutational experiments it was shown 
that the Ser81 phosphorylation was vital for the recruitment of PR and CK2 to progestin 
responsive element 1 and transcription of a gene subset. Furthermore, CK2 is a ubiquitously 
expressed protein and is overexpressed in all cancers known to date and is associated with 
pro-survival and proliferative phenotypes therefore could be contributing towards BCa 
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(Hagan et al. 2011). The MAPKs p42 and p44 were shown to phosphorylate the PR on 
Ser294 after hormone treatment. This caused the PR to become downregulated, which was 
due to a Ser294 phosphorylation dependent degradation by the 26S proteasome. 
Additionally, in a ligand independent manner the 26S proteasome was shown to degrade 
immature PR intermediates by an unknown mechanism (Lange et al. 2000). MEK was also 
shown to phosphorylate the PR at Ser345 in response to hormone. This occurs via the non-
classical mechanism, PR activated the EGFR, c-SRC and MAPK signalling which resulted in 
the Ser345 phosphorylation. This phosphorylation then caused the PR to strongly associate 
and tether with the transcription factor Sp1, resulting in the transcription of p21 and EGFR. 
This transcription occurred on promoter which are not progestin response elements and 
produced a positive feed-forward loop (Faivre et al. 2008). Although undetermined through 
this study, the non-classical signalling of PR could have a large influence on BCa. This 
would occur by upregulation of proliferative pathways such as the MAPK. Furthermore there 
is also evidence of ER signalling similarly activating the MAPK pathway through non-
classical mechanisms in BCa (Santen et al. 2001).  
Considering that PR can be phosphorylated by other MAPKs, the previously described 
cross-talk with CDKs, it is tempting to speculate that RSKs regulates PR activity by directly 
phosphorylating it.  
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4.5 - Future Work 
There are few relationships characterised between the RSKs and the SRs however, both are 
often implicated in hormone driven cancers. The uncharacterised relationships leave a 
knowledge gap across several cancers types concerning the role of RSKs in steroid 
signalling. Furthermore, these cancers cause many deaths each year globally therefore it is 
extremely important to elucidate the RSK/SR relationships. In doing so, it could lead to a 
breakthrough in the understanding in steroid signalling and provide new approaches to 
therapeutic treatments. From this project there were some aspects of work which were 
unsuccessful or due to time constraints could not be started or completed.  
To make this a comprehensive study, the mineralocorticoid receptor needs to be 
incorporated into the mammalian expression vector PSG5 for the use in the same luciferase 
assays. This would then reveal the full extent as to how all RSKs cause changes in all SR 
activities. Additionally, mutagenesis experiments would need to continue for RSK1 to provide 
a full set of RSK mutants. These two processes both failed in laboratory for unknown 
reasons yet were successful for other components, therefore as a precautionary step new 
reagents and primers will be purchased to remove this possibility. Additionally, previous 
notes and protocols will be inspected to check for any inconsistencies or errors.  
Throughout the luciferase assays there has been one condition which is comparable 
between the three experiment types, 100ng concentration of RSK DNA under a constant 
hormone concentration. However, across most of the experiments there are inconsistencies 
between these values. For example, RSK2/3 with the AR have considerably higher values in 
the PMA induction experiments in the -PMA condition than the comparable conditions across 
the other two experiment types. These kinds of discrepancies can also be seen with AR-
RSK1 and GR-RSK4. This could be due to several different variables which can be 
overcome; different batches of DNA used throughout project, different batches of COS-1 
cells used throughout project, different batches of CaCl2 and BBS used throughout project 
and varied freezer incubation times. To overcome these problems fresh DNA for each RSK 
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isoform, SR and the additional luciferase components will be made from the same large 
culture. One new fresh batch of COS-1 cells will be used and the health of the cells will be 
monitored with high attention. One large batch of both CaCl2 and BBS will be made. 
Luciferase assays will be conducted on the day and plates will not be frozen longer than 
mentioned on the protocol.  
In terms of furthering the depth of this project, inhibitor experiments will be created to 
validate the effects caused on SR activity by the RSKs. As with the hormone and DNA 
concentrations, inhibitor optimisation experiments will first be conducted to determine the 
concentration of inhibitor that will not destroy RSK activity but that will allow for a visible 
reduction/increase that can be used to validate RSK effects seen. Mammalian 2 hybrid 
assays will be carried out to determine the mechanism by which the RSKs regulate SRs 
activity. Fusion proteins will be created of both the RSKs and the SRs. This will be done by 
recombinant DNA techniques to incorporate the RSKs and SRs into different domains of the 
Gal4 protein. Gal4 has two different domains, the binding domain (BD) which binds to DNA 
and the activating domain (AD) which is necessary for activating the transcription of the 
reporter gene. If the AD is removed from the BD no transcription occurs, conversely when 
the two domains are near, transcription of the reporter gene occurs. The RSKs will be fused 
to the BD as they don’t possess transcriptional activity and will not interfere with the reporter 
gene thus the SRs will be fused to the AD. This will then provide evidence as to which 
mechanism the proteins interact. If the proteins interact it would indicate that the RSK 
phosphorylates the SR and if they don’t it indicated the RSKs cause this effect via indirect 
mechanisms. In the case of direct phosphorylation there are several additional experiments 
that can be done to further dissect the interaction. The kinase kinetics could be measured 
with a kinase kit. The phosphorylation position could be probed for using phospho-antibodies 
as most phosphorylation site on the SRs are known and are most likely commercially 
available.  
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4.6 - Conclusion 
To conclude, this study used recombinant DNA techniques to prepare the RSKs and SRs for 
a series of luciferase assays. The luciferase assays were used to show the changes in SR 
activity induce by RSKs. RSK1-4 cause an increase in AR and GR activity whilst RSK4 
significantly decreased ERα activity and RSK3 significantly increased PR activity. The use of 
PMA to invoke maximal activity through MAPK pathway activation caused no significant 
change except for 2 isoforms across all PMA induction experiments suggesting the 
endogenous pathway is sufficiently active to activate all over expressed RSKs. The 
phospho-mimetic experiments suggested that the mutation was not sufficient to cause a 
constitutively active protein. These interactions will be further investigated primarily through 
mammalian 2 hybrid assays which will elucidate the mechanism of regulation between each 
RSK isoform and SR of interest. Inhibitor optimisation experiments, followed by inhibitor 
experiments will be used to validate the effects seen by inhibiting the RSKs. Once this data 
is finished it could provide new insight into RSK-SR signalling.  
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